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This thesis examines three factors that affect the prokaryotic transcription cycle; 
Microcin J25, a peptidyl inhibitor of RNAP; Q antiterminator protein, a bacteriophage 
protein that modifies RNAP to readthrough termination signals in phage late genes; and 
Gp33, a T4 phage protein that is a co-activator of T4 phage late gene transcription.  
 
We determined that the Microcin J25 peptide (MccJ25) has a lassoed-tail structure using 
mass spectrometry and NMR. The 21 amino acid MccJ25 peptide is produced from a 58 
amino acid pro-peptide, McjA, that is truncated and post-translationally modified by two 
maturase enzymes. We synthesized McjA and constructed a protein-A tagged 
biosynthesis cassette to be used in the analysis of MccJ25 maturation.  
 
Escherichia coli (Ec) RNAP has not, thus far, been amenable to crystallization despite 
considerable effort. One potential hindrance to crystallization may be the carboxy 
terminal domain of the alpha subunit (α-CTD, residues 249-329) that is connected to an 
amino-terminal domain (α-NTD, residues 8-235) by a 14-residue linker. We successfully 
expressed, purified and crystallized a version of Ec RNAP without the α-CTD.  
  
The Q antiterminator proteins from lambdoid phage, modify Ec RNAP to readthrough 
termination sites within the phage late gene. A structure of Q protein could reveal how Q 
antitermination occurs and may provide insight into the mechanism of termination. We 
developed an improved expression and purification protocol for λQ, and performed 
biophysical characterization on both λQ and the related 82Q. 
 
The T4 phage protein Gp33 is a co-activator that interacts with both Ec RNAP and T4 
DNA replication machinery to upregulate transcription from T4 late promoters. Gp33 is 
thought to have an analogous function to E. coli σ704 in that it binds the beta flap of 
RNAP and helps recruit RNAP to promoters. Ec RNAP bound to Gp33 is recruited to the 
promoter by a unique mechanism through a protein-protein interaction between Gp33 and 
the DNA-bound sliding clamp of the T4 DNA replisome, Gp45.  We obtained crystals of 
Gp33 bound to the Ec Beta flap that diffracted to 3.0 Ångstroms. The preliminary 
structure shows Gp33 as a mainly helical protein that wraps around the Beta flap.  
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Chapter 1: General introduction 
 
1.1 A structure based description of prokaryotic gene transcription  
Gene transcription in all organisms is carried out by DNA-dependent RNA polymerases. 
In bacteria all genes are transcribed by the evolutionary conserved RNA polymerase core 
enzyme (RNAP), a protein complex of about 400 kDa with the subunit composition of 
two alpha, beta, beta prime and omega (α2ββ′ω) 1.  RNAP core is catalytically competent 
to elongate RNA chains from a DNA template. RNAP core can interact non-specifically 
with DNA but must bind an additional factor, sigma (σ), to form the holoenzyme capable 
of specific initiation at promoters 1. The crystal structures of various σ's, the complete 
RNAP core, RNAP holoenzyme, and RNAP elongating complexes (containing DNA 
template and RNA transcript) have provided a structural basis to interpret decades of 
biochemical and genetic analyses into the mechanism and regulation of the transcription 
cycle, (initiation, elongation and termination; outlined in figure 1). 
 
Core assembly begins with the dimerization of the alpha subunits via their amino 
terminal domains (α-NTD), which provides a scaffold for further assembly of the 
complex 2. The β subunit associates to form the α2β subassembly, which then binds the 
β′-ω subassembly to form the complete core 3. The overall structure of the core resembles 
a crab claw, with β and β′ each forming one pincer 4; 5; 6. The catalytic site is located deep 
within the main channel formed between the pincers. The α-NTDs and ω are  bound on 
the outside of the claw and have no direct interaction with the catalytic residues.  
2 
 
3 
  
4 
The RNAP core is approximately 150 Å long, 115 Å tall and 115 Å wide, with an 
internal channel that flexes as wide as 27 Å 4. The internal channel is split by a “wall” 
formed by two β′ helices (β′F & β′G) that extend between the two lobes and separate the 
main channel that accommodates downstream DNA and the RNA-DNA hybrid, from the 
secondary channel that allows nucleotides access to the active site 7; 8. 
 
Initiation of transcription begins with the holoenzyme binding promoter DNA to form the 
closed complex. The specific interactions between the holoenzyme and the promoter 
DNA are provided by the σ subunit, which also mediates DNA melting 5; 9. 
 
σ's are key regulators of transcription. All bacteria contain a primary σ factor that directs 
transcription of essential housekeeping genes. Most bacteria also contain alternative σ's 
that recruit RNAP to their cognate promoters to direct transcription in response to various 
environmental or morphological cues 10. σ's are, in turn, regulated by anti-σ's, anti-anti-
σ's and σ-appropriators 11. Primary σ's recognize promoters containing two hexameric 
consensus motifs; the -10 element (or Pribnow box, consensus sequence TATAAT), and 
the -35 element (consensus sequence TTGACA), centered, respectively, 10 bp and 35 bp 
upstream of the transcription start site, +15. A structure-based sequence alignment based 
on Thermus aquatics (Taq) σA, a primary σ factor, defines four conserved regions, σ1.1, 
σ2, σ3 & σ4, that form distinct structural domains connected by flexible linkers 9. 
Biochemical and genetic experiments indicated that σ2.4 bound the -10 element and σ4.2 
bound the -35 element and that σ formed extensive interactions with RNAP 12. Free, full-
length σ is unable to bind DNA because σ1.1 stabilizes a compact form of σ that cannot 
5 
bind DNA 13. However, in the holoenzyme, σ is in an extended conformation with σ2, σ3 
& σ4 splayed across the upstream face of RNAP, forming extensive protein-protein 
interactions. The σ/RNAP interactions position σ2.4 and σ4 appropriately to make 
specific interactions with the -10 and -35 promoter elements, respectively 6; 14. σ2 is 
bound to the β′ subunit coiled-coil and lid 6; 14. σ3 is bound near the downstream opening 
of the claw and interacts with features from both the β and β’ subunits including the β 
flap and the β’ zipper, zinc-binding domain, lid, coiled-coil and lid 6; 14. σ3 and σ 4 are 
linked by a long linker that winds through the main channel, forming a hairpin loop near 
the active site and occupying the RNA exit channel beneath the β flap 6; 14. 
 
The RNAP holoenzyme has an immobile core and “mobile modules” that move as rigid 
bodies with respect to each other, allowing the claw to open so that RNAP can flexibly 
interact with DNA 14 These mobile modules are the σ4 bound to the β flap, the β’ clamp 
bound to the σ2- σ3 domains, and two portions of the β pincer; β1 and β2 14.  These 
mobile modules would position the σ2 and σ4 domains to interact with the -10 and -35 
element to form the closed complex 6; 14.  
 
Once the closed complex has formed it undergoes a series of isomerization steps that lead 
to the open complex with a melted DNA transcription bubble that extends from 
nucleotides -11 to +4 with respect to the start site at +1 15. In the open complex DNA is 
bent to curve around the RNAP. The DNA melting starts at -11 and is mediated by σ2.3. 
As the strands separate the non-template strand is held by a groove on the outside of the 
enzyme formed between the β1 and β2 domains while the template strand enters the 
6 
catalytic site via a protein tunnel formed by parts of σ, β and β’ 1.  
 
Before RNAP clears the promoter it undergoes multiple rounds of abortive initiation 
whereby short (2-12 nucleotides) RNA transcripts sterically clash with the σ3-σ4 linker 
in the RNA exit channel 14. Region 3.2 of σ stabilizes the initiating nucleotide 29. 
Promoter escape occurs when a longer RNA transcript displaces this linker from the exit 
channel, and during early elongation the transcript must dislodge σ4 from the beta flap to 
emerge from the exit channel, and begin the process of σ release 7. During elongation the 
transcription bubble moves along the DNA and the non-template DNA and template 
DNA re-anneal upon exiting the enzyme 7. 
 
The elongation complex eventually terminates in either a rho-dependent or rho-
independent manner 16. DNA encoded termination signals lead to the formation of RNA 
stem-loop structures that cause the RNAP to pause, and are thought to destabilize the 
nucleic acid-RNAP interaction such that RNAP is released and recycled. 
7 
1.2 Thesis outline 
Factors that modulate, inhibit or subvert the transcriptional machinery are interesting in 
their own right and can provide additional insight into the transcription cycle. This thesis 
examines three such factors; Microcin J25, a peptidyl inhibitor of RNAP; Q 
antiterminator protein, a bacteriophage protein that modifies RNAP to readthrough 
termination signals in phage late genes; and gp33, a T4 phage protein that is a co-
activator of T4 phage late gene transcription.  
 
Mircocin J25 (MccJ25) is a small peptide produced by Escherichia coli (Ec) that inhibits 
RNAP within other Ec bacteria lacking the MccJ25 immunity efflux pump 17; 18; 19. We 
determined that this peptide has a remarkable lassoed-tail structure using mass 
spectrometry and NMR 20; 21; 22. This work is described in chapter 2.  
 
The 21 amino acid MccJ25 peptide is produced from a 58 amino acid pro-peptide, McjA, 
that is truncated and post-translationally modified by two maturase enzymes 23, 24. We 
synthesized McjA and constructed a protein-A tagged biosynthesis cassette to be used in 
the analysis of MccJ25 maturation. However, despite considerable effort, we could not 
develop a system to overexpress these three enzymes. These efforts are described in 
chapter 3. 
 
Genetic and biochemical evidence suggest that MccJ25 binds with the secondary channel 
17; 18; 19; 25. Indeed, these studies provide further support for this channel being the 
nucleotide access pathway to the catalytic core. A crystal structure of MccJ25 bound to 
8 
RNAP would reveal the mechanistic details of inhibition, but MccJ25 does not inhibit 
either of the bacterial RNAPs that have been crystallized. It would be very useful to have 
a crystal structure of the very well characterized Escherichia coli  (Ec) RNAP for 
structural studies with the various factors such as mccJ25 that specifically target Ec 
RNAP. The successful expression, purification and crystallization of Ec RNAP is 
described in chapter 4. 
 
The Q antiterminator proteins from lambda phage, and related phages, modify Ec RNAP 
to readthrough termination sites within the phage late genes 26. It is thought that 
termination at these sites is caused by mRNA hairpin loop formation as at standard 
intrinsic termination sites, but the molecular mechanism of Q antitermination is not 
understood. A structure of Q protein could reveal how Q antitermination occurs and may 
provide insight into the mechanism of termination. To this end, I developed an improved 
expression and purification protocol for Q, and performed biophysical characterization. 
These efforts are detailed in chapter 5. 
 
The T4 phage protein Gp33 is a coactivator that interacts with both Ec RNAP and T4 
DNA replication machinery to upregulate transcription from T4 late promoters 27. Gp33 
is thought to have an analogous function to Ec σ704 in that it binds the beta flap of RNAP 
and helps recruit RNAP to promoters 28. In contrast to σ704, however, T4 Gp33 does not 
interact with DNA, and T4 late promoters do not have a -35 element. Ec RNAP bound to 
Gp33 is recruited to the promoter by a unique mechanism through a protein-protein 
interaction between Gp33 and the DNA-bound sliding clamp of the T4 DNA replisome, 
9 
gp45 27.  We obtained crystals of Gp33 bound to the Ec beta flap that diffracted to 3.0 
Ångstroms and were able to solve the structure. The preliminary structure is discussed in 
chapter 6. 
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Chapter 2: The Structure of Microcin J25, a Peptide inhibitor 
of Bacterial RNA Polymerase, is a Lassoed Tail 
J Am Chem Soc. 2003 Oct 15;125(41):12475-83. Structure of microcin J25, a peptide 
inhibitor of bacterial RNA polymerase, is a lassoed tail. Wilson KA, Kalkum M, Ottesen 
J, Yuzenkova J, Chait BT, Landick R, Muir T, Severinov K, Darst SA. 
 
2.1 Introduction  
DNA-dependent RNAP, the central enzyme of bacterial gene expression, is a complex 
molecular machine 1,2. The catalytically competent core RNAP has subunit composition 
α2ββω and a total molecular weight near 400 kDa. In contrast to the ribosome, 
surprisingly few small-molecule inhibitors specific for bacterial RNAPs have been 
described, despite their potential as tools to investigate RNAP mechanism as well as for 
antibacterial drugs. Only one inhibitor, rifampicin (or its derivatives), has reached 
medical use 3, where it is a key component of anti-tuberculosis therapy. Thus, recent 
findings that an antibacterial peptide, Microcin J25 (MccJ25), functions through 
inhibition of the bacterial RNAP 4,5 has generated wide interest.   
 
MccJ25 is a 21-residue, ribosomally-synthesized peptide 6,7 produced by strains of Ec 
harboring a plasmid-borne synthesis, maturation, and export system 8. MccJ25 exhibits 
bacteriocidal activity against a range of Gram-negative bacterial species 6. Genetic and 
15 
biochemical results suggest that MccJ25 inhibits transcription by binding within the 
RNAP secondary channel 5, a 12-15 Å diameter channel that branches off from the main 
active site channel, through which the nucleotide substrates can diffuse to the enzyme 
active site 9,10. Binding of MccJ25 within this channel could block nucleotide substrates 
from entering the enzyme active site. An important step towards further understanding 
and manipulating the activity of MccJ25 is the characterization of its chemical and three-
dimensional structure. 
 
On the basis of biochemical and NMR studies, the primary structure of MccJ25 was 
reported to be a 21-residue, head-to-tail cyclic peptide, [cyclo(-
G1GAGHVPEYF10VGIGTPISFY20G-), or G1GAGHVPEYF10VGIGTPISFY20G, using a 
numbering scheme where G1 is the N-terminally coded amino acid of the mature peptide] 
and the three-dimensional solution structure was reported 7,11.  Here, we start with the key 
observation that synthetic peptides based on this reported structure are biologically 
inactive. We show, using a combination of biochemical studies, mass spectrometry, and 
NMR, that the reported cyclic structure is incorrect, and that the peptide contains an 
extraordinary structural fold. The structure contains a lactam linkage between the α-
amino group of Gly1 and the γ-carboxyl of Glu8, forming an 8-residue ring (Gly1-Glu8) 
that we term the lariat ring. The ‘tail’ (Tyr9-Gly21) passes through the lariat ring, with 
Phe19 and Tyr20 straddling each side of the lariat ring, sterically trapping the tail within 
the ring in a noncovalent interaction that is resistant to strongly denaturing conditions. 
We call this structure a lassoed tail.   
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2.2 Experimental Section 
 
2.2.1 General Materials and Methods. All amino acid derivatives and resins were 
purchased from Novabiochem (San Diego, CA) except Boc-L-Glu(OAllyl)-OH and Boc-
Gly-PAM resin, which were purchased from Neosystems (Strasbourg, France). All other 
chemicals were purchased from Sigma-Aldrich Chemical Co (St. Louis, MO). 
Thermolysin was purchased from Calbiochem (Darmstadt,Germany). Analytical gradient 
HPLC was performed on a Hewlett-Packard 1100 series instrument withdetection at 214 
and 280 nm. Analytical HPLC was performed on a Vydac C18 column (5 micron, 4.6 x 
150 mm) at a flow rate of 1 mL/min. Preparative HPLC was routinely performed on 
aWaters DeltaPrep 4000 C18 column (15-20 micron, 50 x 250 mm) at a flow rate of 5 
mL/min. Twosolvent systems were used on linear gradients; 1) 0.1% aqueous TFA 
(solvent A) vs. 90% Acetonitrile plus 0.1% TFA (solvent B); 2) 0.05% aqueous TFA 
(solvent C) vs. methanol plus 0.05% TFA (solvent D). 
 
2.2.2 Bacterial culture and microcin purification. MccJ25 was purified from minimal 
M9 media plus1% glucose and 1 mg/ml thiamine as previously described 7 except that 
the E.coli strain, SBG231(AB259) sjmA1; spontaneous MccJ25 resistant mutant, 
β'T931I; 4) was transformed with the pTUC200 plasmid; a pBR322 backbone with a 13 
Kb insert encompassing McJ genes A, B, C, and D. 
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2.2.3 Activity assays. For the in vitro abortive initiation transcription assay, Ec RNAP 
holoenzyme was combined with the T7 A1 promoter-containing DNA fragment, CpA 
primer, and [α-32P]UTP in the presence and absence of the natural and synthetic 
microcin variants at indicated concentrations 5. Reactions were incubated at 37°C for 10 
min, and the products were resolved by denaturing PAGE and visualized by 
autoradiography. For the in vivo assay, an agar overlay assay test was used 5. Double 
dilutions of MccJ25 variants (10 µL) were applied to a solid LB plate, allowed to dry, 
and overlaid with 2 mL top agar (0.7%) containing a 200 µL stationary phase innoculate 
of sensitive (AB259) or resistant (SBG231) Ec. The plates were incubated overnight at 
37°C and examined for zones of inhibition. 
 
2.2.4 Peptide Synthesis. General: All peptides were synthesized according to the in-situ 
neutralization/HBTU activation protocol for Boc SPPS 12. Following chain assembly, 
global de-protection and cleavage from the support was achieved by treatment with HF 
containing 4% v/v p-cresol, for 1 hour at 0°C. Following removal of the HF, the crude 
peptide products were precipitated and washed with anhydrous cold Et2O before being 
dissolved in aqueous acetonitrile (50% B) and lyophilized. 
 
2.2.4 a) Peptide 1: Linear Microcin = NH-GGAGHVPEYFVGIGTPISFYG-OH. The 
peptide was synthesized (0.5 mmole scale) on a PAM resin. Following chain assembly 
and global deprotection/cleavage, the crude material was purified by RP-HPLC (50-60% 
D over 60 min.) to give the desired material, peptide 1, which was characterized by MS; 
found m/z 2125.71 ± 0.05, expected 2125.36, and MS2; fragmented with appropriate b 
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and y ions series for this sequence. 
2.2.4 b) Peptide 2: Cyclic cysteine Microcin = GGAGHVPEYFVGIGTPICFYG. The 
synthesis of circular peptide 2 by native chemical ligation 13 required the preparation of a 
linear peptide α-thioester precursor corresponding to the permuted and mutated microcin 
sequence; CFYGGGAGHVPEYFVGIGTPI, where the underlined residue indicates a 
Ser-Cys mutation. This sequence was synthesized (0.25 mmole scale) on a 3-
mercaptopropioamide derivatized MBHA resin 13. Following chain assembly and global 
deprotection/cleavage, the 3-mercaptopropioamide-(DNP-His)-peptide (found m/z 
2393.16 ± 0.74; expected 2394) was cyclized by dissolving the crude lyophilized material 
(50 mg, 20.9 mmole) in ligation buffer (6 M guanidine-HCl, 100 mM Tris, pH 8.5, 1 mM 
EDTA, 0.1 M mercaptoethanesulfoninc acid) to a final concentration of 400 µM. The 
reaction was deemed complete after stirring at room temperature for 16 hours, at which 
point the reaction mixture was purified directly by preparative RP-HPLC (27-43% B 
over 60 min.). This yielded the desired cyclic, fully deprotected peptide (8 mg, 3.8 
µmole) with 95% purity and 16% yield (from the 3-mercaptopropioamide-[DNP-His]-
peptide), which was characterized by MS; found m/z 2123.18 ± 0.71, expected 2123. 
 
2.2.4 c) Peptide 4: Lariat Microcin = GGAGHVPEYFVGIGTPISFYG. The peptide 
was synthesized (0.5 mmole scale) on a PAM resin. In order to allow on-resin cyclization 
between the α-amino and Glu8 γ-carboxyl groups, the side-chain of Glu8 was 
orthogonally protected as an allyl ester. Following chain assembly and Nα deprotection, 
the allyl group was removed by treatment with Pd(PPh3)4. The desired lactam linkage 
was then formed on the solid phase using PyBOP (5 eq.) as the activating agent and 
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either DMF or DMSO as the solvent. Cyclization was monitored using the quantitiative 
ninhydrin test, which indicated that the coupling efficiency reached a maximum of ~50% 
after three 15 minute coupling procedures. Following global deprotection/cleavage, the 
crude material was purified by RP-HPLC (50-60% D over 60 min.) to give the desired 
material, peptide 4, (4.5 mg, 2.1 µmole; 2% yield, based on original loading of the resin), 
which was characterized by MS; found m/z 2107.03 ± 0.01, expected 2107.03, and 
MS2; fragmented with appropriate b and y ions series for this sequence (Figure 2C). The 
purified material contained a small amount of a peptidic contaminant with m/z 2244. 
 
2.2.5 Thermolysin cleavage of MccJ25.  
2.2.5 a) Extensive digestion: MccJ25 (10 ng, 4.7 pmole) in 5 µL water, was digested 
with 1000 U thermolysin (suspended in 10 mM Tris-HCl pH 8.0) for two hours at room 
temperature. An aliquot of this digestion mixture (1 µL) was diluted ten-fold with 
aqueous 0.1% TFA, absorbed to a ZipTip microcolumn (Millipore), washed with 20 µl of 
0.1% aqueous TFA, and eluted with 1 µL half-saturated 2,5-dihydroxy benzoic acid 
solution (see above) directly onto a MALDI target for analysis.  
 
2.2.5 b) Minimal digestion. MccJ25 (7.4 mg, 3.5 mmole) in 20 µL 18.75 mM ammonium 
bicarbonate, pH 8.0, was digested with 1 U thermolysin (suspended in 10 mM Tris-HCl 
pH 8.0) for one hour at room temperature. The digestion was stopped by addition of 25 
µL 100 mM EDTA. The digestion mixture was diluted with methanol to a final 
concentration of 45% methanol, centrifuged at 12,000 rpm for 2 min, and the supernatant 
warmed at 45°C for 5 min. The singly-cleaved peptide was purified by analytical RP-
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HPLC on a 30 min, 45-60% methanol gradient at 45°C to give the desired material at 
~83% purity, which was characterized by MS; found m/z 2125.01 ± 0.01, expected 
2125.36, and MS2; found appropriate y and b series for a single cleavage between 
between Phe10 and Val 11. This peptide was sequenced by Edman degradation at the 
Protein Chemistry Laboratory of The University of Texas Medical Branch, Galveston, 
TX. 
 
2.2.6 Treatment of Digested MccJ25 with denaturing agents. The remaining extensive 
digestion mix (from above) was diluted 10-fold with 0.1% aqueous TFA, and 4 µL 
aliquots were incubated with each of the following treatments at both room temperature 
and 95°C for 1 hour; 1 M NaOH, 5 M guanidine-HCl, 50% TFA, or 1% SDS (all final 
concentrations). Each sample was then diluted five-fold with 0.1% aqueous TFA, except 
the 50% TFA condition, which was diluted with H20. A portion of each sample (1 µL) 
was then analyzed by MALDI. 
 
2.2.7 Mass spectrometry. Aliquots (1 µL) of peptide solution (0.5 – 0.1 pmol/µL) were 
applied onto the MALDI compact disk-sample plate 14 and mixed with equal volumes of 
half-saturated 2,5-dihydroxy benzoic acid (DHB) in 50% methanol/20% 
acetonitrile/0.1% TFA and allowed to dry. Accurate masses of the peptides 1-4, and of 
proteolytic cleavage products, were measured using a prototype MALDI-QqTOF 
instrument 15. The MS2 and MS3 experiments were performed as desribed 16 using a 
prototype MALDIquadrupole ion trap 14. Ion injection durations were 200-400 msec. 
Resonant excitation was performed using empirically optimized instrument specific 
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parameters (isolation width: 2.5 Da, normalized collision energy: 35-38%, activation Q: 
0.240, activation time: 300 msec). Spectral acquisition times varied from 30 sec to 1!min 
in order to achieve acceptable signal/noise ratios. 
 
2.2.8 NMR Spectroscopy. MccJ25 (4 mg, 1.9 µmole) and synthetic lariat (4 mg, 1.9 
µmole) were dissolved in 500 µL d6-DMSO, and spectra were acquired on a Bruker 
DMX500 spectrometer. Spectra were processed using NMRPipe17 and analyzed using 
NMRView 18. The synthetic linear peptide (2.2 mg, 1.0 µmole) was dissolved in 500 µL 
d3-CD3OD, and spectra were acquired on a Bruker DPX400 spectrometer, and processed 
using XwinNMR. All spectra were acquired at 298K.  
  
Sequence-specific backbone and sidechain assignments for MccJ25 were derived from 
TOCSY and NOESY (250 ms, 175 ms, 100 ms mixing time) data. A total of 274 NOESY 
peaks were assigned. Crosspeak intensities were measured at a NOESY mixing time of 
175 ms, and NOE-derived constraints were generated and sorted into strong (1.8-2.8Å), 
medium (1.8-3.4Å), or weak (1.8-5.0Å) bins. Protons were not assigned 
stereospecifically; spectrally differentiable protons were collapsed to pseudoatoms, 
yielding 192 constraints and distance corrections were handled internally within the 
software suite CNS 19. 
 
 
2.2.9 Structure Determination. A total of 192 distance constraints [of which 79 were 
intra-residue, 59 sequential, 9 medium range (|i - j| < 4 Å) and 45 long range (|i - j| >/= 4 
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Å)] were utilized in distance geometry simulated annealing calculations 20 using the 
standard CNS protocol, with a modified protein parameter file to allow for the isopeptide 
amide bond between Gly1 and Glu8. A total of 75 embedded substructures were 
generated from the lariat peptide in an extended starting conformation. All embedded 
starting structures, irrespective of energies, were used to generate 75 final structures by 
NOE-restrained molecular dynamics simulated annealing, followed by an additional 
minimization step with reduced dependence on NOE constraints. The 20 lowest energy 
structures were selected for analysis. No NMR constraint violations >0.5 Å were 
observed in these 20 structures. A Ramachandran plot revealed that 46.2% of the dihedral 
angles fell in the most favored region, 53.9% fell in additionally allowed regions, and the 
remaining 7.7% fell in the generously allowed region.  
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2.3 Results and Discussion 
2.3.1 The structure of MccJ25 requires reassessment. The biological activity of totally 
synthetic versions of MccJ25 was assessed in order to evaluate methods for the 
preparation of large amounts of highly pure, biologically active MccJ25 required for 
structural studies of the RNAP/MccJ25 complex (Figure 2.1a). An intramolecular version 
of native chemical ligation was used to synthesize peptide 2 (Figure 2.1a), where Ser18 
of the coded MccJ25 sequence (1, Figure 2.1a) was mutated to provide the required N-
terminal Cys residue 21. In addition, cyclic peptide 3 (Figure 2.1a), with the coded 
MccJ25 sequence obtained by a native chemical ligation scheme followed by 
desulfurization 22, was a generous gift of P.E.Dawson.  
 
Two tests of biological activity were used, in vivo (killing of sensitive bacterial cells) and 
in vitro (inhibition of transcription activity by purified Ec RNAP) 5. Each of the synthetic 
peptides 1, 2, and 3, were totally inactive in vivo (not shown) and in vitro (Figure 2.1b). 
For instance, 10 µM MccJ25 (purified from MccJ25 producing Ec) 7 reduced 
transcription to 43% of the level in the absence of MccJ25 (Figure 2.1b, lanes 1 and 2), 
while 50 µM MccJ25 nearly completely inhibited transcription (19%, lane 3). In contrast, 
concentrations of 2 and 3 up to 400 µM (the highest concentration tested) showed no 
inhibition.  
 
The behavior of MccJ25 and 3 was also compared by analytical reversed phase HPLC. 
The retention time of MccJ25 was 13.8 min on a 45 min, 50-65% methanol gradient 
using a C18 column, whereas the retention time of 3 was 21.0 min.  
25 
Finally, MccJ25 and 3 were compared by mass spectrometric analysis (Figure 2.2). The 
m/z of MccJ25 and 3 were both measured to be 2107.0, which is 18 Da lower than that of 
the linear form (peptide 1). The MALDI-ion trap mass spectrometric fragmentation 
spectrum (MS2 spectrum) of MccJ25 was characterized by an intense peak arising 
through the loss of water from the parent ion and a series of low intensity b-ions (b8 to 
b20; Figure 2.2a). This spectra was compared to the MS2 spectrum of 3 (Figure 2.2b), 
which displayed a low intensity series of fragment ions characteristic of a cyclic peptide 
16, with fragment masses distinct from those of MccJ25. 
 
In summary, peptide 3 did not behave like MccJ25 in three significant tests. First, 3 was 
inactive in in vivo and in vitro assays of biological activity at concentrations up to 400 
µM, while MccJ25 showed significant transcription inhibition at 10 µM (Figure 2.1b). 
Second, 3 and MccJ25 had significantly different retention times by reversed phase 
HPLC. And third, the MS2 spectra of 3 and MccJ25 were very different (Figures 2.2a, b). 
Together, these observations conclusively establish that the structure of MccJ25 is not 3. 
 
2.3.2 Mass spectrometric analysis of MccJ25. Further fragmentation of the smallest 
observable ion of the MccJ25 MS2 series, the b8-ion (Figure 2.2a, magnified in Figure 
2.3a), led to an MS3 spectrum characteristic of the unbranched, 8-residue cyclic moiety 
shown in Figure 2.3b 16. These data (Figures 2.3a and 2.3b) are consistent with the 
presence of an isopeptide bond between Gly1 and Glu8, as confirmed in subsequent 
experiments (see later). We therefore synthesized a peptide that incorporated this putative 
Gly1 to Glu8amide linkage (‘lariat’, peptide 4 of Figure 2.1a). However, the lariat 
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peptide 4 showed no in vivo (not shown) or in vitro activity (Figure 2.1b). MS2 
fragmentation of 4 was compared to that of MccJ25 taken under identical instrumental 
settings (Figure 2.2a versus 2.2c). The same b-ion series was observed for both peptides, 
but, surprisingly, the intensity of the lariat-derived series was approximately two orders 
of magnitude higher (when normalized to the intense water loss peak) than that obtained 
from MccJ25. Comparison of the spectra in Figure 2.2, all of which were derived from 
peptides with identical molecular masses, demonstrated that the synthetic peptides, 3 and 
4, were structurally distinct from MccJ25. More detailed comparison between the MS2 
spectra of natural MccJ25 and 4 revealed several peaks unique to MccJ25 (colored red in 
Figure 2.3a). For example, the unique peak at m/z 1948.9 appeared to arise from the loss 
of G14T15 from the parent ion at m/z 2107.0. This loss can only be explained if residues 
16–21 were connected in some way to the N-terminal part of the peptide. We indicate this 
unknown N- to C-terminal “connection” by the dashed line in Figures 2.2, 2.3, and 2.4. 
Further fragmentation of the MS2 fragment at m/z 1948.9 (MS3 experiment) confirmed 
this connectivity through observation of the sequential losses of P16I17 and S18FYG21 
(Figure 2.3c). These data demonstrate that the C-terminal part of MccJ25 (beyond residue 
17) is attached to the N-terminal part (before residue 12) firmly enough to survive both 
the MALDI process and the subsequent collision induced dissociation. The observation 
of other unique MS2 fragments at m/z 1778.6 (loss of G12IGT15), m/z 1738.6 (loss of 
G14TPI17), and m/z 1568.7 (loss of G12IGTPI17) further supports the existence of the 
putative connection between the C- and N-terminal parts. This connection is mysterious, 
as it results in no apparent change in mass.  
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Further insight into structural differences between MccJ25 and 4 was obtained by mass 
spectrometric analysis of proteolytic fragments derived from thermolysin digestion. 
Treatment of MccJ25 with low quantities of thermolysin resulted in cleavage of the 
peptide bond between Phe10 and Val11, yielding a single chemical species with m/z 
2125.0, as reported previously (in the context of the erroneous structure 3) 7,23. This result 
is inconsistent with the primary structure of 4, since cleavage between Phe10/Val11 
would yield two peptide fragments. Experiments with larger amounts of thermolysin 
produced three major degradation products at m/z 1968.9, 1487.7 and 1015.5 (Figure 
2.4a). The ion at m/z 1015.5 corresponds to the truncated lariat moiety containing the first 
eight amino acids and the short Y9F10-tail, G1GAGHVPEYF10. The ion at m/z 1487.7 
corresponds to the protonated truncated lariat moiety, G1GAGHVPEYF10, plus the 
peptide S18FYG21. The latter 4-residue peptide contains a free amino- and carboxyl-
terminus, as verified by subjecting the peptide at m/z 1487.7 to mass spectrometric 
fragmentation (Figure 2.4e). Likewise, the ion at m/z 1968.9 arose from protonated 
G1GAGHVPEYF10 + I13GTPISFYG21. Thus, we find that the unique connection between 
the C- and N-terminal portions of MccJ25 is at least partially stable under the conditions 
of enzymatic digestion. The nature of this connection was further investigated by 
treatment of the thermolysin digested peptide with denaturing agents. Treatment with 1% 
SDS, 6 M guanidine-HCl, or 0.1% TFA had no effect on the connection, even after one 
hour incubations at 95°C, implying the connection was stable to these denaturing 
treatments.  
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Additional information on the chemical nature of the mysterious N- to C-terminal 
connection was obtained by subjecting the thermolysin generated MccJ25-digest to 
partial hydrolysis with NaOH (Figure 2.4b). The peptide bond between Gly1 and Gly2, 
within the lariat ring, was labile to base treatment, leaving a branched product with a 
mass 18 Da higher than that of the truncated lariat (Figure 2.4b, peak doublet at m/z 
1015.47 and 1033.46). The identity of this branched product was verified by MS2 
fragmentation of the m/z 1033.46 ion (Figure 2.4d). In addition a peak at m/z 954.49 
appeared, which we identified as the C-terminal tail, I13GTPISFYG21 (Figure 2.4c). 
These observations are consistent with hydrolysis of the ring, allowing release of the C-
terminal tail. This hypothesis was further supported by the lack of peak doublets for the 
products at m/z 1968.95 and 1487.66 (Figure 2.4b), indicating that these structures 
retained the intact ring and associated C-terminal tail. Finally, under MS2 conditions, the 
labile bond between Val6 and Pro7 dissociated (verified by MS3 experiments), leading to 
release of S18FYG21 (Figure 2.4e). 
 
2.3.3 NMR analysis of MccJ25. The structure of MccJ25 was further analysed using 1H-
NMR experiments. No sequential NOE crosspeaks were observed between Gly21 and 
Gly1, either in our experiments or in previously reported experiments, 7 an observation 
inconsistent with structure 3. However, strong NOEs between Gly1 NH and the sidechain 
protons of Glu8 were observed in NOESY spectra of MccJ25 (Figure 2.5a), consistent 
with the formation of the lactam linkage.  
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The 1H-NMR spectra of MccJ25 displayed significant chemical shift dispersion, typical 
of a highly structured peptide (Figure 2.5b). While the chemical shifts of the NH protons 
ranged from 6.8 to 9.4 ppm, the NH chemical shifts of residues 10-17 were all clustered 
between 7.9 and 8.5; the large chemical shift dispersion was due primarily to residues 1-9 
and 18-21. This disparity is especially interesting in light of the MS2 analysis of the 
thermolysin cleavage experiments, which indicated an association between the lariat 
residues and the C-terminus of the peptide (Figure 2.4). While peptide 4 also contains the 
lactam linkage between Gly1 and Glu8, the NH chemical shifts ranged only from 7.3 to 
8.6 ppm, typical of a random coil structure (Figure 2.5b). Similarly, the spectra of linear 
peptide 1 showed NH chemical shifts ranging from 7.7 to 8.5 ppm (data not shown).  
 
The wide dispersion of chemical shifts allowed for the unambiguous assignment of 274 
peaks in the NOESY spectrum of MccJ25. Several interesting long-range interactions 
were observed between the Cterminal tail of the peptide and the N-terminal lariat ring. In 
particular, Phe19 and Tyr20 define two independent clusters of long-range NOEs. For 
example, NOE connectivities were observed between the ring protons of Tyr20 and the 
sidechains of Val6 and Glu8 but not Pro7, and between the Tyr20 NH and backbone 
protons of ‘lariat’ residues 5-8. On the other hand, the ring protons of Phe19 interacted 
solely with the sidechains of ‘tail’ residues 16-18 and ‘lariat’ residue Pro7 (but not Val6 
or Glu8), and the protons of Phe19 interacted with backbone protons of ‘lariat’ residues 
3-7. NOE crosspeaks between the side-chains of Phe19 and Tyr20 were conspicuously 
absent. 
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A model structure consistent with the NMR distance information was calculated. 
Specifically, 192 NOEderived distance constraints were utilized in hybrid distance 
geometry simulated annealing, using the covalent structure of 4 as the starting point. An 
ensemble of 20 structures was generated that converged to a common fold with RMSD 
for backbone atoms of 1.73 +/- 0.54 Å, and for heavy atoms of 2.38 +/- 0.55Å (Figure 
2.6a). Residues 18-20 and 1-8 represented an area of well-defined structure, with 
backbone (including Glu8 sidechain) RMSD of 0.91 +/- 0.24 Å and heavy atom RMSD 
of 1.36 +/- 0.27 Å.  
 
The calculated structure closest to the mean of the ensemble was selected as a 
representative structure (Figures 2.6b, 2.6c, 2.6d). The clusters of interactions involving 
Phe19 and Tyr20 define an unusual structure, in which the tail residues 18-21 are 
threaded through the lariat ring formed by the backbone of residues 1-7 plus the sidechain 
of Glu8. The bulky sidechains of Phe19 and Tyr20 straddle the lariat, protruding on either 
face of the loop.  
 
Two distinct topologies are possible for the tightened noose structure, depending on 
which direction the C-terminal tail passes through the lariat ring. In the low-energy 
structures, only one topology was observed (Figure 2.6). This topology is consistent with 
the NOE clusters described above, where interactions between tail residues Phe19 and 
Tyr20 with lariat residues Val6 and Pro7, respectively, define opposite faces of the lariat 
ring (Figure 2.6b). 
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2.4 Conclusions 
Here, we establish that the previously proposed structure for MccJ25 7,11 is incorrect. 
Synthetic peptides based on this structure (2, with a single Ser-Cys mutation at position 
18, and 3, identical to the proposed structure) differ from MccJ25 in three important 
ways. First, they are biologically inactive (Figure 2.1b). Second, they behave differently 
by reversed phase HPLC. Third, they behave differently upon mass spectrometric 
fragmentation analysis (Figure 2.2). We show that MccJ25 contains a lactam linkage 
between the α-amino group of Gly1 and the γ-carboxyl of Glu8, forming an 8-residue 
ring (Gly1-Glu8, the lariat ring). Our data suggests that the C-terminal 'tail' of MccJ25 
(Tyr9-Gly21) is trapped within the lariat ring. Release of the C-terminus is prevented by 
steric hindrance and requires the cleavage of at least one peptide bond, which must occur 
either within the ring or, based on the NMR data, between residues Phe19 and Tyr20. The 
tail-free lariat observed at m/z 1015.47 (Figures 4a and 4b) may have arisen from 
thermolysin digestion of the bond between Phe19 and Tyr20, but additional experiments 
are required to establish this hypothesis.  
 
Our MccJ25 model (Figure 2.6) is consistent with all of our biochemical and mass 
spectrometric fragmentation results, and is strongly supported by the NMR analysis. In 
retrospect, the previously published experimental support for 3 as the structure of MccJ25 
was not conclusive 7. We re-evaulate the previous interpretations in light of our new 
results in the following four points: 
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1) The N- and C-termini of MccJ25 were blocked to Edman and carboxypeptidase Y 
sequencing, respectively 6,7. In fact, the blocked N-terminus is due to the lactam linkage 
with the g-carboxyl of Glu8. The inability to sequence from the C-terminus by 
carboxypeptidase Y is not evidence that the C-terminus is engaged in a chemical linkage, 
but can also be explained by steric considerations since the large protease must be able to 
bind the C-terminus of its substrate. In our model of the MccJ25 structure, the two C-
terminal residues of the peptide are not freely accessible, being engaged in non-covalent 
interactions with the lariat ring (Figure 2.6). 
 
2) Partial acid hydrolysis of MccJ25 yielded peptide fragments, two of which were 
analyzed by N-terminal sequencing (fragment H-9II, corresponding to 
G1GAGHVPEYF10VG, and H-10II, corresponding to Y9FVGIG) and these results were 
cited in support of 3 7. Since these peptide fragments did not contain a peptide bond 
linking Gly21 with Gly1 (Figure 2.1a), they neither support nor contradict 3. However, 
the observed fragments are consistent with our model with the assumption that the harsh 
acid hydrolysis conditions cleaved the lariat -ring lactam linkage. 
 
3) Thermolysin digestion, which cleaved between Phe10 and Val11, yielded a single 
peptide 7, as expected from 3. However, a more thorough analysis of the results of 
thermolysin digestion (Figure 2.4) supports our model. 
 
4) The most compelling evidence that the structure of MccJ25 corresponded to 3 was the 
previously published N-terminal sequence analysis, by Edman degradation, of 
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thermolysin cleaved MccJ25 7. The proteolytic cleavage of the peptide bond between 
Phe10 and Val11 was interpreted to generate a linear peptide with a free N-terminus, 
allowing N-terminal sequencing to begin at Val11. Blond et al. (1999) 7 report the 
following sequencing results: V11GIGTPISFY20G21G1GAG4. Sequencing through the C-
terminal Gly21 to Gly1 and on to Gly4 supports 3 and contradicts our model. For this 
reason, we analysed our own sample of thermolysin-cleaved MccJ25 by Edman 
degradation. We obtained the sequence from Val11 through Gly21, followed by several 
cycles indicating Gly, which is expected behavior for the C-terminal residue of a peptide 
(J. S. Smith, personal communication). Importantly, in cycles subsequent to Gly21, none 
of the amino acids expected in the N-terminal region of MccJ25 (other than Gly) were 
observed. For example, Ala or His (expected at positions 3 and 5 of the coded MccJ25 
sequence, Figure 1a) were not observed. Thus, we believe our Edman degradation results 
are consistent with our model, since the precise identification of the C-terminal residue 
by this technique is imprecise.  
 
Although the previously published NMR structure for MccJ25 11,23 does not have the 
correct covalent linkages, the previous structure and our structure (Figure 2.6) are quite 
similar when considering the well defined portion of our model. The α-carbon backbone 
of residues 4-8 and 19-20 of our model can be superimposed onto the corresponding 
atoms of the previous structure with an RMSD of 1.13 Å.  
 
In principal, the final test of the MccJ25 structure should come from its total chemical 
synthesis and comparison of its biological activity with MccJ25. Due to the nature of the 
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structure, with its sterically trapped tail, total chemical synthesis has so far proven 
unsuccessful (data not shown). In this case, the pathway to the final structure must be 
critical, since the MccJ25 precursor must fold into a pre-defined conformation prior to the 
lariat ring cyclization to allow steric trapping of the C-terminal tail (Figure 2.6). Pre-
folding of the MccJ25 structure may be a function of the McJA pro-protein, or may be 
assisted by one of the processing enzymes.  
 
Synthesis of active MccJ25 in vivo requires the action of two processing enzymes, McJB 
and McJC 8,24,25,26 , which act on the McJA pro-protein to produce the mature MccJ25 
peptide. McJB and McJC are both necessary and sufficient for the in vitro maturation of 
MccJ25 25,26. Interestingly, McJC shows sequence and predicted structural homology 27 
with a group of related ATP/Mg2+-dependent enzymes including class B asparagine 
synthetases (that convert aspartic acid to asparagine; 28,29) and β-lactam synthetase 
(catalyzes the formation of the b-lactam ring in clavulanic acid) 30,31, suggesting McJC is 
an ATP/Mg2+-dependent enyzme that catalyzes the formation of the lactam ring found in 
MccJ25. A sequence analysis of McJB revealed two putative functional domains; an N-
terminal domain with weak homology to mammalian adenosine kinases and a C-terminal 
domain with homology to cysteine preoteases 26 suggesting that McJB cleaves the McJA 
pro-protein. 
 
The lassoed-tail structure has been observed previously in small peptide inhibitors 32. In 
some cases, this architecture appears to be supported by a network of covalent linkages, 
including disulfide bonds 32,33 , while in one case the tail appears to be sterically trapped 
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within the ring, as is the case with MccJ25 34. 
 
An NMR analysis of the thermolysin-cleaved MccJ25 found that the two-chain peptide 
retained the structure of the native MccJ25 in the structural “core” consisting of the 8-
residue lariat and the lassoed four residue tail (S18FYG21) whereas the cleaved beta-
hairpin made up by residues 11-16 was disordered 35. This structured core was apparent 
in our analyses and remained intact in the gas phase (Fig. 2.4). 
 
Two shorter variants of the two-chain peptide produced by extended thermolysin 
digestion MccJ25(Δ11-12) 36 and MccJ25(Δ13-17) 37 were found to retain in vitro 
transcription inhibition activity but were inactive in vivo suggesting that the core is 
sufficient to bind and inhibit RNAP whereas the beta-hairpin is necessary for import. In 
support of this a recent systematic structure-activity analysis found that the beta-hairpin 
residues could be substituted for other amino acids without any effect on in vitro 
transcription 38. This structure-activity analysis further defined two groups of residues 
essential for 1) production; Gly1, Gly2 and Glu8 and 2) in vitro inhibition of RNAP; 
Gly4, Pro7, Tyr9, Phe10, and Phe19 38. These two sets of residues were inferred to form 
surface recognition determinants for 1) the MccJ25 maturation enzymes and 2) RNAP 38  
but an alternative interpretation is that the second set of residues are essential for the 
lassoed-tail structure; both Gly and Pro affect local conformational flexibility and may 
affect the flexibility of the lariat, and Phe19 could only be substituted by either Trp or 
Tyr reflecting the importance of a bulky residue to sterically hinder the release of the tail. 
Thus, the inference that these residues form a hydrophobic recognition patch 38 will have 
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to be evaluated by further studies.  
 
Modeling studies indicated MccJ25 (Figure 2.6b) is an appropriate size and shape to bind 
in and block the RNAP secondary channel, as suggested from biochemical and genetic 
experiments 5, 39. However, these models were based on the intact MccJ25 and need to be 
re-evaluated with regard to the rigid core of MccJ25 being necessary and sufficient for 
RNAP inhibition.  The structure of either MccJ25 or the MccJ25 “core” bound to RNAP 
would provide further insights to the mechanism of inhibition.  
 
Our investigations into the processing pathway of MccJ25 will be discussed in chapter 3.  
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Chapter 3: The biosynthetic pathway of Microcin J25 
3.1 Introduction 
MccJ25 contains an internal lactam linkage between the α-amino group of Gly1 and the 
γ-carboxyl of Glu8. The tail (Tyr9-Gly21) passes through the ring (Gly1-Glu8), with 
Phe19 and Tyr20 straddling each side of the ring, sterically trapping the tail in a 
noncovalent interaction we call a lassoed tail 1, 2, 3. The biosynthesis of MccJ25 is 
dependent on a plasmid-borne synthesis, maturation, and export system that involves just 
four genes, mcjABCD, found within a 4.8 Kb contiguous sequence on the naturally 
occurring 50 Kb plasmid, see table 3.1 4 . The mcjA gene encodes a 58-residue precursor 
that includes the 21 amino acids found in the mature form of MccJ25 at the carboxyl-
terminus, preceded by 37 amino acids that are cleaved during maturation 5. The mcjB and 
mcjC genes encode maturase enzymes essential for microcin biosynthesis 5, 6. The mcjD 
gene has high homology to ABC exporters and is believed to export MccJ25, thus 
conferring host immunity 5. The processing pathway of MccJ25 is particularly attractive 
for study as the genetic system has been defined and includes only two maturase 
enzymes, McjB and McjC (See fig. 3.1). 
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MccJ25 bactericidal activity acts against a range of Gram-negative bacterial species 7 and 
this activity could potentially be exploited as a drug. However, such use would be fairly 
restricted as uptake requires the FhuA receptor protein and the TonB pathway 8, and 
activity is confined to Gram negative RNAP. Nevertheless, an understanding of the 
biosynthetic pathway for MccJ25 may allow the development of novel drugs 
incorporating the lassoed tail structure. This secondary structure is not novel and has been 
observed in other peptidyl inhibitors 9 -it allows short peptides to adopt defined tertiary 
structures akin to mini-proteins and confers an impressive stability, rendering them 
impervious to denaturing agents, heat and some proteases 3. 
 
Table 3. 1 Characteristics of the ORFs of the MccJ25 cluster. 
 
Protein Gene 
size (bp) 
Predicted protein size 
Amino acids      kDa 
Homology Proposed 
function 
McjA 174 58 6.2 Other 
lariat 
peptides 
MccJ25 
precursor 
McjB 624 208 24.6 Adenosine 
kinase 
MccJ25 
maturation 
McjC 1542 514 58.7 b-lactam 
synthetase 
MccJ25 
maturation 
McjD 1,740 580 65.4 ABC 
exporters 
MccJ25 
export 
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We set out to biochemically characterize this biosynthetic pathway with the goal of 
crystallizing the enzymes to gain a detailed knowledge of MccJ25 maturation. The first 
part of our experimental plan was to set-up an in vitro maturase assay using a synthetic 
peptide corresponding to the full-length McjA precursor protein with McjB and McjC 
purified as recombinant proteins. We hoped to follow intermediate steps in the 
maturation using mass spectrometry. We then intended to crystallize McjB and McjC to 
obtain detailed information about the catalytic steps in biosynthesis. 
 
The mcjB, mcjC and mcjD genes are encoded on a polycistronic mRNA, the Shine-
Delgarno sequence of mcjC is before the stop codon of mcjB, and only two base pairs 
separate each of the three open reading frames 6; 10 These characteristics suggest that 
expression of these genes will be coupled at both the transcription and translation levels, 
and that the products may functionally and physically interact 11; 12. Therefore, we tried to 
co-express these proteins as a binary complex and as a ternary complex with mcjD.  
 
Despite extensive efforts, we were unable to overexpress mcjB or mcjC to the levels 
required for structural studies. Meanwhile, other groups were successful at setting up in 
vitro McjA maturation systems. A simple in vitro assay using a membrane fraction 
extract from cells carrying a plasmid-borne MccJ25 operon was able to mature a 
recombinant 58-amino acid mcjA precursor protein to the active 21-residue, cyclized 
form 13. A more sophisticated in vitro assay using purified hexahistidine-tagged mcjB and 
McjC demonstrated that McjB and McjC were necessary and sufficient to catalyze the 
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maturation 6. Our results are presented below and are discussed in context of the other 
groups’ successes. 
 
3.2 Methods 
3.2.1 Peptide Synthesis. General: The synthesis of the full length 58-amino acid 
precursor peptide required the preparation of a 32-amino acid a-thioester peptide and a 
26-amino acid N-terminal-cysteine peptide which were joined by native chemical ligation 
14. Both peptides were synthesized according to the in-situ neutralization/HBTU 
activation protocol for Boc SPPS 15. Following chain assembly, global de-protection and 
cleavage from the support was achieved by treatment with HF containing 4% v/v p-
cresol, for 1 hour at 0˚C.  Following removal of the HF, the crude peptide products were 
precipitated and washed with anhydrous cold Et2O before being dissolved in aqueous 
acetonitrile (45% v/v) and lyophilized. 
 
Peptide 1: α-Thioester peptide  = MIKHFHFNKLSSGKKNNVPSPAKGVIQIKKSA. 
The peptide was synthesized (0.3 mmole scale) on a 3-mercaptopropioamide derivatized 
MBHA resin 14. Following chain assembly and global deprotection/cleavage, the crude 
material was purified by RP-HPLC (17.1-30.6% acteonitrile over 60 min.) to give the 
desired material, which was characterized by ESI-MS; found mass 3622, expected 3621. 
 
Peptide 2: Cysteinyl peptide = CQLTKGGAGHVPEYFVGIGTPISFYG. The native 
chemical ligation reaction requires an N-terminal cysteine residue, therefore the N-
terminal fragment was synthesized with a mutated sequence where the underlined residue 
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indicates a Ser-Cys mutation. The peptide was synthesized (0.3 mmole scale) on PAM 
resin. Following chain assembly and global deprotection/cleavage, the crude material was 
purified by RP-HPLC (18-36% acteonitrile over 45 min.) to give the desired material, 
which was characterized by ESI-MS; found mass 2698, expected 2698.  
 
Native chemical ligation. Only a small scale ligation has been completed. The purified 
lyophilized peptides were dissolved in ligation buffer (6 M guanidine-HCl, 100 mM Tris, 
pH 8.5, 1 mM EDTA, 200 mM mercaptoethanesulfoninc acid), peptide 1 was dissolved 
at a final concentration of 1.6 mM, peptide 2 was dissolved at a final concentration of 5 
mM. The reaction was deemed complete after stirring at room temperature for 66 hours, 
at which point the reaction mixture was analyzed by analytical RP-HPLC (20-40% B 
over 60 min.). This yielded the desired full-length peptide, which was characterized by 
MS; found mass 6216 expected 6215. 
  
3.2.2 Cloning and protein expression in standard pET vectors  
A plasmid carrying the MccJ25 expression cassette, pTUC100, was a gift from Raul 
Salomon. The microcin expression cassette was cut from pTUC100 and cloned into a 
pBR322 backbone via the HindIII/SalI sites to form pKW2. 
 
Each of the MccJ25 maturase genes were PCR amplified from pTUC100 as a single or 
multi-gene ORF and cloned into a pET28a-based vector between NdeI/BamHI sites as a 
hexahistidine-fusion protein to generate pSKB2-mcjB, pSKB2-mcjC, pSKB2-mcjBC, 
pSKB2-mcjBCD.  An additional co-expression system was made by first cloning the 
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PCR amplified mcjC gene into pet21a to generate pET21a-mcjC, and then PCR 
amplifying this plasmid from upstream of the rbs and subcloning this fragment into 
pSKB2-mcjB to generate pSKB2-mcjB-rbs-mcjC.  
 
For a typical expression trial Ec Rosetta2(DE3) (Novagen) cells were transformed with 
each of these plasmids  and grown in LB plus 50 µg ml−1 kanamycin at 37°C to mid-log 
phase and then expression was induced with 1 mM isopropyl β-d-thiogalactopyranoside 
for 1-4 hours. Cells were harvested by centrifugation, resuspended in SDS-PAGE loading 
buffer and heated at 95°C and examined for protein content by SDS-PAGE followed by 
Coomassie blue staining. In other expression trials various factors differed; Ec 
BL21(DE3) was used,  MagicMedia (Invitrogen) or M9 media were used, and cells were 
grown at various temperatures ranging from 18°C - 37°C. In some cases the cells were 
lysed by sonication in lysis buffer and separated into soluble and insoluble fractions by 
centrifugation. 
 
3.2.3 Cloning and protein expression of MBP-mcjA  
The mcjA gene was PCR amplified from pTUC100 and cloned into the pMAL-c2X 
plasmid (NEB) and expressed in Ec  ER2508 cells as described above for the pET vectors 
in BL21(DE3).  
 
3.2.4 Cloning and protein expression of protein A-tagged mcjB within pTUC200 
A proteinA-tagged McjB (prA-McjB) fusion was made using overlapped PCR fragments. 
Fragment A consisted of DNA upstream of the mcjB gene with 5’ HindIII site and 3’ 
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DNA that had homology to fragment B. Fragment B consisted of the prA gene with 
homology to fragment A at the 5’ end and homology to fragment C at the 3’ end. 
Fragment C consisted of the mcjB gene downstream DNA to the unique BstXI site with a 
5’ NheI site homology to fragment B. The three fragments were fused together and 
extended with a short PCR cycle followed by amplification of the entire insert using 
primers matching to the 5’ end of fragment A and the 3’ end of fragment C. The blunt 
ended PCR product was ligated into the pCR-Blunt plasmid then cloned into pKW2 via 
the HindIII/BstXI sites replacing the untagged mcjB within the mccJ25 expression 
cassette to generate pKW4. 
 
Coli#55_prA::rpoC are an environmental Ec strain modified to encode protein-A tagged  
rpoB described in Savalia et al. J Mol Biol. 2008 377(3): 774–789. Ec MG1655 or 
Coli#55_prA::rpoC cells were transformed with pKW4 and grown in mimimal M9 media 
at 37°C for 12 hours beyond stationary phase to induce microcin expression. Cells were 
harvested by centrifugation, washed once with ice-cold 10% (v/v) glycerol, and frozen as 
pellets in liquid nitrogen. Cells were cryogenically disrupted with a Retsch MM301 
mixer mill (Retsch) that was maintained at liquid nitrogen temperature, and stored at 
minus 80°C. 
 
3.2.5 Western blot analysis of protein A-tagged mcjB  
Frozen cell lysate  (0.5 g) were suspended in 2.5 ml of extraction buffer (20 mM Hepes 
(pH 7.4); 2 mM MgCl2; 150 mM NaCl) supplemented with 200 µg/mL PMSF and 4 
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µg/mL pepstatin with or without detergent; SDS v/v 0.1%, 1%, octylglucoside v/v 0.5%, 
1%, 2%, Tween v/v 0.1%, 0.5%, 1%, Triton v/v 0.1%, 0.5%, 1%. 
 
Resuspended cells were mixed with 0.002 % (w/v) DNase I (Sigma-Aldrich) and slowly 
spun at room temperature for 15 minutes. The lysate was clarified by centrifugation for 
10 min at 13,000 rpm; the supernatant was decanted and centrifuged for another 10 min 
at 13,000 rpm and decanted again to generate the soluble fraction and insoluble pellet. 
The two fractions were dissolved in SDS-PAGE loading buffer and heated at 95 °C for 
five minutes and then resolved by SDS-PAGE with 4-12 % (w/v) Bis-Tris 
polyacrylamide gels (Invitrogen). Proteins were visualized by Coomassie blue staining.  
 
These protein samples were also examined by Western Blotting with anti-prA antibodies 
using the Western Lightning chemiluminescence kit (Perkin Elmer). 
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3.3 Results 
3.3.1   McjA was insoluble when expressed as a hexahistidine fusion protein, and 
was degraded when expressed as a MBP fusion protein.  
 
We first tried to obtain the full-length McjA protein by expressing it as a hexahistidine 
fusion protein (his6-McjA) with the intention of purifying it with a Ni+-affinity column. 
Unfortunately, the vast majority of his6-McjA protein was insoluble under standard 
inductions conditions and when expressed at low temperature (see fig. 3.2). 
 
To obtain soluble McjA protein we cloned and expressed mcjA as a maltose-binding-
protein fusion (MBP-McjA).  Initial expression trials indicated that MBP-McjA was 
expressed to a reasonable level using a standard induction protocol. However, it was 
apparent from the SDS-PAGE analysis that the mcjA portion of the MBP-McjA fusion 
protein was degraded during expression such that one could see a doublet of bands on a  
SDS PAGE gel corresponding to MBP-McjA (48.7 kDa) and MBP alone (42.5 kDa, see 
fig. 3.3, lane 3). In the subsequent attempts to purify MBP-McjA we found that we were 
unable to obtain the desired full-length MBP-McjA. 
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3.2   McjA was synthesized in two pieces and then ligated using native chemical 
ligation to produce the full-length peptide. 
 
As we were unable to obtain McjA as an expressed recombinant fusion protein, we 
decided to use solid phase peptide synthesis. McjA is a 58-amino acid peptide that would 
be technically difficult to synthesize as a single peptide. Therefore, we synthesized the 
peptide in two pieces; peptide 1, a 32-residue thioester corresponding to the amino-
terminus and peptide 2, a cysteine-substituted 26-residue peptide corresponding to the 
carboxyl-terminus (see fig. 3.4). Both peptides were obtained in high purity as assessed 
by analytical HPLC (see fig. 3.5 and 3.6). The purified peptides were joined by native 
chemical ligation and the final product was purified by preparative HPLC to obtain 2.3 
mg of full-length mcjA at about 70% purity (see fig. 3.7, 3.8 and 3.9).  (This final yield 
was from a small scale preparation using only a portion of the purified peptides.) This 
peptide was sent to our collaborator (Konstantin Severinov) for further characterization. 
 
3.3.3 The mcJC gene was incorrectly defined in the literature and actually extends 
beyond the published stop codon. 
The microcin J25 operon was sequenced 10, however, after a number of expression 
constructs showed an apparent frameshift error in the mcJC gene we sent the pTUC200 
plasmid for additional sequencing. We found that the mcjC gene extended to 1542 bp and 
encoded 514 amino acids rather than the previously published 1326 bp. This extension 
results in just 2 bp separating the mcjC gene from the mcjD, just as only 2 bp separates 
the mcjB and mcjC genes. 
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3.3.4 The expression of recombinant MccJ25 maturase enzymes was undetectable in 
cell lysates analyzed by SDS-PAGE and stained with Coomassie Blue. 
 
Each of the MccJ25 maturase genes (mcjB & mcjC) were cloned into expression plasmids 
as both single and multi-gene operons as described in table 3.2. These constructs were 
tested for expression under standard conditions or in non-standard conditions with 
various temperatures and various amounts of inducer (IPTG), and even substituting LB 
with the autoinducing Magicmedia (Invitrogen), but there was no expression detectable 
by Coomassie staining of cell lysates separated by of SDS-PAGE. An example 
expression trial is shown in figure 3.10. 
 
3.3.5     Rare codon usage in mcjB and mcjC is high. 
 
The poor expression of mcjB and mcJC was surprising considering that these are Ec 
proteins being expressed in Ec cells. Such poor expression is sometimes associated with 
heterologous expression when the origin genome has a different codon bias to the 
expression host. Therefore, we analyzed the codon usage of these genes by comparing 
codon usage to that in genes highly expressed during exponential phase (E.coli Codon 
Usage Analysis 2.0 by Morris Maduro). 
 
The mcjB gene contains 208 codons, 25% of these are below a 10% threshold for codon 
usage. This includes 5 pairs of adjacent rare codons and 1 cluster of three in a row. The 
mcJC gene contains 531 codons, 23% these are below a 10% threshold for codon usage 
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with 17 adjacent pairs of rare codons, 3 clusters of three in a row and 1 cluster of four in 
a row. For comparison, the subunits of the Ec RNAP contained far fewer rare codons 
with each subunit scoring between 1% and 7% (see Table 3.3). 
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Table 3.2 Plasmids used in the study of the MccJ25 biosynthesis pathway. 
 
Name Description Expression products 
pTUC100 pTUC200  HindIII digest fragment inserted 
into pBR322. 
MccJ25 operon 
pKW2 pTUC100 HindIII/SalI digest fragment 
inserted into pBR322. 
MccJ25 operon 
pKW4 pKW2 with a substituted protein A-tagged 
McjB  
MccJ25 operon with 
proteinA-tagged McjB  
pMAL_A mcjA  inserted into the NEB pMAL-C2X 
plasmid 
MBP-McjA 
pSKB2-mcjA mcjA  inserted into the Novagen pet28a-
based plasmid, pSKB2, via NdeI/BamHIII 
sites. 
McjA 
pSKB2-mcjB mcjB  inserted into the Novagen pet28a-
based plasmid, pSKB2, via NdeI/BamHIII 
sites. 
McjB 
pSKB2-mcjC mcjC  inserted into the Novagen pet28a-
based plasmid, pSKB2, via NdeI/BamHIII 
sites. 
McjC 
pSKB2-
mcjBC 
mcjB and mcjC  inserted as a polycistronic 
sequence into the Novagen pet28a-based 
plasmid, pSKB2, via NdeI/BamHIII sites. 
McjB & McjC 
pSKB2-mcjB-
rbs- mcjC 
mcjB  inserted into the Novagen pet28a-
based plasmid, pSKB2, via NdeI/BamHIII 
sites. 
McjB & McjC 
pSKB2-
mcjBCD 
mcjB, mcjC and mcjD  inserted as a 
polycistronic sequence into the Novagen 
pet28a-based plasmid, pSKB2, via 
NdeI/BamHIII sites. 
McjB & McjC & 
McjD 
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Table 3. 3 Rare codon bias in the microcin maturase and export enzymes. 
 
Gene Size of 
protein;  
number of 
codons, 
molecular 
weight 
(kDa),  
Fraction of 
codons below 
10% usage in 
highly 
expressed 
proteins. 
Number of 
adjacent 
pairs of 
rare 
codons 
Number of 
adjacent 
triplets of 
rare 
codons 
Number of 
additional 
clusters 
mcjB 209, 24.6  25% 5 1 0 
mcjC 514, 58.7 23% 17 3 1 cluster of 4 
mcjD 581, 65.4 30% 25 12 1 cluster of 5,  
1 cluster of 6 
Ec 
rpoA 
329, 36.5 7% 2 1 0 
Ec 
rpoB 
1343, 150.6 2% 1 0 0 
Ec 
rpoC 
1407, 155.1 1% 1 0 0 
Ec 
rpoZ 
92, 10.2 3% 0 0 0 
Ec 
rpoD 
614, 70.2 3% 1 0 0 
 
3.3.6 Western blotting could follow protein A-tagged McjB expression. 
One method to visualize low abundance protein expression is to use Western Blot 
analysis. Rather than raise antibodies to the MccJ25 maturase enzymes, the McjB protein 
was expressed as a protein-A fusion protein (prA-McjB) that could be probed using anti-
prA antibodies. 
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The prA-mcjB fusion gene was subcloned into the native MccJ25 expression cassette to 
generate plasmid pKW4. To test for competent MccJ25 expression this construct was 
transformed into MG1655 cells, grown to stationary phase and the growth media was 
applied to a C8 cartridge and a MccJ25 containing fraction was eluted with 100% 
methanol. This fraction was confirmed to contain MccJ25 by mass spectrometric analysis 
(data not shown) and by bioassay (see fig 3.11). 
 
A time course of PrA-McjB expression, examined by Western Blot analysis, revealed that 
McjB expression was switched on during early-exponential phase and continued to 
accumulate throughout later growth phases (see fig. 3.12). The expression levels of mcjB 
were compared to expression levels of rpoC during this same experiment by expressing 
pKW4 in an Ec strain modified with a chromosomal proteinA::rpoC gene 
(Coli#55_prA::rpoC). McjB protein levels were comparable to those of the Ec RNAP 
beta’ subunit – a surprisingly high expression level considering that the Ec RNAP is an 
abundant protein (see fig. 3.12B the higher band corresponds to prA-rpoC and the lower 
band corresponds prA-mcjB). 
 
Further experiments indicated that PrA-McjB was insoluble in the standard lysis buffer; 
therefore we tested whether adding detergents might improve its solubility. While a mild 
detergent, octylglucoside, actually made the protein more insoluble, SDS and Tween did 
improve the solubility (see fig. 3.13).  
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3.4 Discussion 
The lack of detectable protein expression from our hexahistidine recombinant expression 
vectors impeded any further progress in this project. Why were we unable to detect 
protein expression when other groups were able?  
 
Duquesne et al. 6 used very similar pET vectors and used the standard expression strain 
BL21(DE3) to successfully express hexahistidine-tagged McjA, McjB and McjC.  The 
most likely explanation for their success is that they used more discriminating tools for 
detecting expression and were satisfied with very low yields. Proteins were detected by 
tryptic digest of gel bands followed by mass spectrometry. Their reported yields were 40 
ug/L for His6-McJB and 200 ug/L for His6-McjC after a single chromatographic 
purification step. These yields and this one-step purification would not suffice for 
crystallography purposes but were sufficient for a biochemical analysis.  
 
In a similar strategy to our PrA-McJB strategy, Clarke and Campopiano 16 appended a 
hexahistidine-tag to the mcjC gene within the native operon and followed expression and 
purification by Western blot analysis. They did not obtain the maturase enzymes in a 
biochemically pure state, but rather obtained a detergent extract of the membrane fraction 
in which they detected His6-McjC by Western lot. This extract was successfully used in 
vitro to mature recombinant McJA to the active form.  
 
In contrast, Duquesne et al. 6 obtained soluble proteins by inducing at expression at low 
temperature, –15°C, and purified both His6-McjB and His6-McjC by standard 
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chromatographic techniques, which they then combined in an in vitro MccJ25 maturase 
assay using His6-McjA as the substrate. 
 
Although Duquesne et al. 6 purified His6-McjA from the soluble fraction they found that 
the protein was highly susceptible to cellular proteases and was rapidly degraded, similar 
to our finding that the soluble MBP-mcjA protein was rapidly degraded. Clarke and 
Campopiano 16 obtained recombinant mcjA by expressing it as a keto-steroid isomerse 
fusion (KSI-mcjA) that was targeted to inclusion bodies and was extracted with 6 M 
Guanidine HCl. In retrospect we should have worked with the insoluble His6-McjA 
protein rather than undergo the arduous task of chemical synthesis. 
 
From our chemical synthesis efforts we obtained approximately 2.3 mg of 70% pure 
peptide. Again with the benefit of hindsight, we should have further purified this peptide 
and retained it for biochemical analysis. It would have been interesting to examine 
whether this peptide had any intrinsic structure by NMR analysis. Duquesne et al. 6 
reported that the McjA protein has some sequence similarity to a serine peptidase and 
may have some autolytic activity. They also found that a linear peptide corresponding to 
the 21 residues found in MccJ25 was not a substrate for the McjB-McjC maturase 
enzymes. It would be interesting to probe which residues of the 37-amino acid leader are 
important for maturation.  A mutational analysis of the 21 C-terminal residues of McjA 
corresponding to MccJ25 found that Gly38, Gly39 and Glu45 (Gly1, Gly2 and Glu8 in 
MccJ25) were absolutely restricted to the wildtype residues for microcin production in 
vivo 17. The catalysis of the lactam bond between Gly1 and Glu8 must therefore require 
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the small, flexible di-Gly and the longer sidechain of Glu (even a Glu>Asp substitution 
was not tolerated).  
 
Even though both Duquesne et al. 6 and Clarke and Campopiano 16 were able to produce 
MccJ25 in vitro, there is still no detailed understanding of the MccJ25 biosynthesis. The 
actual steps in the maturation are not known, the roles of each protein have not been 
defined, and no intermediary products have been characterized. Our prA-McJB construct 
could allow the MccJ25 maturase complex to be immunoisolated on Dynabeads 
(Invitrogen) conjugated with IgG and might provide an alternative in vitro assay that 
would not require the individual recombinant proteins to be expressed and purified. 
Crystal structures of McJB and McJC could still provide mechanistic details that are 
lacking.  
 
Both the mcJB and mcJC genes have a very high rare codon bias, which is thought to 
strain the translation machinery and result in poor and faulty expression 18. This rare 
codon usage may be an evolved strategy for ensuring that MccJ25 production is low 
enough to ensure that it is efficiently removed from the host cell before it can target an 
essential cell function; transcription by RNAP. Thus, generating sufficient McjB and 
McjC for crystallography studies may require synthetic gene design to remove the rare 
codon bias, in vitro gene expression to prevent problems with toxicity, and a system that 
couples transcription to translation to promote protein solubility (eg. 19; 20, ). These 
solutions are becoming cheaper and more efficient and may be a feasible option for future 
studies. 
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Chapter 4. Expression, purification and crystallization of 
Escherichia coli ΔαCTD-RNAP 
 
4.1 Introduction 
Gene transcription in all organisms is carried out by DNA-dependent RNA polymerases 
(RNAPs). The crystal structures for two thermophilic eubacterial, multi-subunit RNAPs 
have been solved; Thermus aquaticus (Taq)1 and Thermus thermophilus (Tth)2. The genes 
encoding RNAP have been highly conserved throughout evolution and these structures 
have provided immense insight into the transcription mechanism. However, the model 
organism for prokaryotic cells is Escherichia coli (Ec), a mesophilic, Gram-negative 
bacteria. More research has probably been done on this organism than any other, and the 
Ec RNAP and regulation of the transcription system is by far the best studied and 
characterized.  The Taq RNAP structure has been fit into a 15-Å resolution cryo-electron 
microscopy reconstruction of the Ec RNAP revealing that these highly conserved 
enzymes are globally similar apart from the addition of three large insertions in the Ec β 
and β’  subunits 3 .  A higher resolution crystal structure of Ec RNAP would allow finer 
details of these differences to be examined and would provide insight into functional 
differences between these enzymes. Crystals of Ec RNAP could also be soaked with 
various co-factors that have been found to specifically affect transcription in E. coli.  For 
instance, there would be the potential for crystals to be soaked with inhibitors such as 
microcinJ25, which does not inhibit either Taq or Tth.  
 
Ec RNAP has not, thus far, been amenable to crystallization despite considerable effort. 
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One potential hindrance to crystallization may be the carboxyl-terminal domain of the 
alpha subunit (α-CTD, residues 249-329) that is connected to an amino-terminal domain 
(α-NTD, residues 8-235) by a 14-residue linker 4. This long, flexible linker tethers each 
α-CTD monomer to the main body of the core enzyme, allowing interaction with 
upstream DNA elements or DNA-bound activators to upregulate transcription 5. These 
interactions are essential in vivo but this flexibility is a potential source of disorder in 
crystals. In all of the crystal structures of Taq or Tth RNAP, the  -CTDs are disordered. 
In contrast, the α-NTD is structurally integrated into the main body of the core enzyme. 
Indeed, the α-NTD homodimer serves as a scaffold for the assembly of the core enzyme 
6. Ec RNAP lacking the α-CTD (RNAPΔα-CTD) has been previously produced by in 
vitro assembly from individual recombinant subunits (eg. Tang et al. 12), however, such 
preparations are unlikely to result in well-folded, homogenous preparations suitable for 
crystallization.  
 
With this in mind, we set out to develop an expression and purification system for Ec 
RNAP lacking the α-CTD (RNAPΔα-CTD) to facilitate crystallization. This system 
would be based on plasmid expression in Ec and therefore needed to consider that the 
host RNAP subunits could intermingle with plasmid-encoded subunits. Thus, the host Ec 
strain would have to be engineered to contain a matching α-CTD on the chromosome and 
the α-CTD would have to be removed post-expression because it is essential in vivo. 
Therefore, we used an inducible expression plasmid with the Ec RNAP genes encoding 
β, β’ and ω with a α subunit modified with a protease restriction site encoded within the 
α-NTD-CTD linker for removal of the α–CTD, and a decahistidine-tag appended to the 
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amino-terminus for purification; α_ppx234-241_CTD(His)10. Expression from this 
plasmid was induced in a specialized host strain chromosomally modified to express the 
same α.  The Ec RNAP produced from this system was screened for candidate 
crystallization conditions and a resulting “hit” was obtained, reproduced and improved, 
but was not ultimately suitable for data collection.  
 
4.2 Methods 
4.2.1 Expression and purification of Ec RNAPΔα-CTD 
A recombinant rpoA gene was designed with the CTD-NTD linker (234-241) substituted 
with a PreScission Protease™ (Amersham) cleavage site, LEVLFQGP, and with an 
uncleavable decahistidine tag appended 3’ to the rpoA gene followed by a downstream 
thermostable kanamycin resistance cassette.  The resultant DNA and protein sequences 
are appended to this chapter (Appendix 4.6). This gene was first cloned into a pet21a 
vector for trial expression and cleavage and was then sub-cloned into an E. coli 
expression vector, pVS6 (a gift from Robert Landick) to generate pVS10. Both these 
plasmids and the pACYCDuet1_rpoZ plasmid encoding E. coli  rpoZ were provided by 
Lars Westblade. The BL21(DE3) rpoA_ppx_CTD(his)10 strain was provided by Imran 
Husnain and Mark Thomas. 
 
BL21(DE3)_rpoA_ppx_CTD(his)10 transformed with both pVS10 and 
pACYCDuet1_rpoZ were grown at 37°C in LB plus 200 ug/mL ampicillin to mid-log 
phase, then the temperature was reduced to 30°C and expression induced by addition of 
isopropyl β-d-thiogalactopyranoside to 1 mM. After 4 hours induction, cells were 
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harvested by centrifugation, resuspended in lysis buffer (50 mM Tris-HcL, pH 8, 5% 
glyverol, 1 mM EDTA, pH 8.0, 5 mM DTT, 1 mM PMSF, EDTA-free protease-inhibitor 
cocktail (Sigma) and lysed by French Press. DNA binding proteins were precipitated 
from the clarified cell lysate with polymin P added to a final concentration of 0.6%. The 
polymin P precipitate was pelleted by centrifugation and then washed with TGED buffer 
(10 mM Tris-HCl, pH 8.0, 5% glycerol, 0.1 mM EDTA, 1 mM DTT) containing 0.5 M 
NaCl. This wash step was repeated. Proteins were then eluted from the polymin P pellet 
with TGED buffer containing 1 M NaCl. The elution step was repeated twice and pooled. 
Protein in the eluant was precipitated by the addition of ammonium sulfate to a final 
concentration of 350 g/L.  The ammonium sulfate precipitate was pelleted by 
centrifugation, resuspended in IMAC-A buffer (20 mM Tris pH 8.0, 1 M NaCl, 5% 
glycerol, 0.5 mM β-mercaptoethanol) and applied to an an IMAC HiTrap column (GE 
Healthcare) charged with Ni2+ ions and pre-equilibrated with IMAC-A buffer. The 
column was washed with 20 column volumes of IMAC-A plus 5 mM imidazole and then 
10 column volumes each of IMAC-A plus 20 mM imidazole, IMAC-A plus 25 mM 
imidazole, IMAC-A plus 60 mM imidazole, IMAC-A plus 80 mM imidazole, IMAC-A 
plus 100 mM imidazole. Proteins bound to the column were eluted with IMAC-A plus 
250 mM imidazole. The eluted proteins were digested overnight with PreScission 
protease (GE Healthcare) and simultaneously dialyzed against IMAC-A buffer at 4°C 
before being applied to a second, subtractive, IMAC HiTrap column to remove non-
specific and uncleaved protein. The flowthrough was dialyzed against TGED buffer 
containing 0.1 M NaCl and applied to a BioRex70 (Bio-Rad) column thad had been 
preequilibrated with TGED buffer containing 0.1 M NaCl. The column was washed with 
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two column volumes of TGED buffer containing 0.1 M NaCl and bound proteins were 
eluted with a linear gradient of 0.2 M – 1 M NaCl in TGED buffer.  Fractions containing 
core RNAP were precipitated with the addition of ammonium sulfate to the final 
concentration of 350 g/L. The ammonium sulfate precipitate was pelleted by 
centrifugation, resuspended in TGED buffer containing 0.5 M NaCl, and further purified 
by size-exclusion chromatography on a SD200 column (GE Healthcare).  
 
Fractions containing RNAP were dialysed into storage buffer; 150 mM NaCl, 10 mM 
TrisCl pH 8.0, 1% glycerol, 5 mM DTT, 10 mM MgCl2, 5 mM B-ME and concentrated 
using centrifugal concentrators (Vivaspin, 100, 000 MWCO). 
 
4.2.2 Crystallization of Ec RNAPΔα-CTD 
An extensive number of vapor diffusion crystallization trials were conducted using 
various commercial screens; JCSG+, Protein Complex, MPD, PEG suite II (all from 
Qiagen Research), Natrix, MembFac, Classics Lite, PEG-ION (Hampton Research). A 
single candidate condition was identified; MembFac#23, 0.1 M ADA buffer pH 6.5, 0.1 
M lithium sulfate, 12% polyethylene glycol 4,000, 2% (v/v) isopropanol. Further vapor 
diffusion crystallization trials were setup based on MembFac#23 varying the temperature, 
pH and polyethylene glycol 4,000 concentration and screening commercial additive 
screens; Additive Screen, Detergent Screens I-III and Silver Bullets (Hampton Research) 
and OptiSalts (Qiagen Research). 
 
Seedbeads (Hampton Research) were used to make seed stock from crystals grown over 
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MembFac#23 and dilutions of this seed stock were used as an epitaxial seed to re-screen 
the MembFac, Natrix, and PEG/IONs (Hampton Research) suites as well as grid screens 
around MembFac#23.  
 
4.2.3 Data collection and processing 
Diffraction images were collected at the at X3A, National Synchrotron Light Source 
(NSLS), Brookhaven National Laboratory (BNL) and at the 24-ID-E, Advanced Photon 
Source, (APS), Argonne National Laboratory (ANL). The data was processed with 
HKL2000. 
 
 
4.3 Results 
 
4.3.1 Ec RNAPΔα-CTD with stochiometric amounts of ω was purified in quantities 
suitable for crystallography 
The linker region between the α-CTD and α-NTD has been shown to tolerate 
substitutions, therefore a recombinant rpoA gene was designed to incorporate a 
PreScission protease (ppx) cleavage site within this linker as well as a decahistidine tag at 
the amino terminus to facilitate purification of this modified RNAP and removal of the 
cleaved α-CTD by metal-affinity chromatography. This modified gene rpoA_ppx234-
241_CTD(his)10 was cloned into a standard expression vector, pet21a (Novagen), and 
the expression and purification of this subunit alone was tested. The α_ppx234-
241_CTD(His)10 protein was well expressed under standard expression conditions and 
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cleavage with ppx went close to completion (data not shown). Therefore, this modified 
gene was sublconed into a recombinant RNAP expression vector replacing the standard 
rpoA gene to generate pVS10. The expression and cleavage of α_ppx234-
241_CTD(His)10 within the context of the core RNAP was also very good, however, the 
purified protein contained full-length α from the BL21(DE3) chromosomal expression. 
Therefore, a strain of BL21(DE3) incorporating the modified rpoA gene was generated 
by our collaborators; Imran Husnain and Mark Thomas.  
 
Ec RNAPΔα-CTD expressed from pVS10 in BL21(DE3)_rpoA_ppx234-241(his)10 was 
purified by an arduous protocol (see fig. 4.1 and methods for details) that resulted in 
highly pure protein. In the initial preparations we suspected that the ω subunit was 
present in sub-stochiometric amounts based on SDS-PAGE and Coomassie blue staining 
of  purified protein. This has been previously observed for preparations of RNAP from 
non-recombinant expression systems. This was confirmed by Electrospray Ionisation–
Mass Spectrometric analysis (ESI-MS) of the intact RNAPΔα-CTD. We compared 
RNAP prepared from either endogenous expression or recombinant expression with and 
without a supplementary ω-expression plasmid (rRNAPΔα-CTD and rRNAPΔα-CTD 
+ω). In all three cases we found two series of ions corresponding to the intact RNAP and 
RNAP minus the 10 kDa ω subunit. For the endogenous RNAP and for rRNAPΔα-CTD 
+ω the peaks corresponding to RNAP minus ω were much smaller than those 
corresponding to the intact RNAP. However, in the case of the recombinant RNAP 
prepared without a supplementary ω-expression plasmid the two peaks were equal in 
size. Although ESI-MS is not strictly quantitative it does give some indication to the 
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relative quantities of two species. In light of these results, we included a tandem ω 
expression plasmid, pACYC_rpoZ in our preparations, to increase the ω content. Typical 
yields for the highly pure RNAPΔα-CTD were 3 mg/L of culture. 
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4.3.2 Crystals of Ec RNAPΔα-CTD diffracted to 10 Ångstroms, and after various 
improvements, to 8 Ångstroms. 
 
An initial screen of 96 crystallization reagents (Hampton Research Natrix and MembFac) 
produced a single candidate hit – small urchins. These urchins diffracted weakly to 10 Å 
at the X3A beamline at BNL. Further screening of additional 600+ conditions failed to 
produce an improved candidate condition. Initially these crystals were only reproducible 
from some preparations and not others. After the addition of the extra ω expression 
cassette these crystals could be reliably reproduced from every preparation. 
 
The initial hit was improved by screening around the crystallization condition, varying 
the pH and precipitant concentration. This led to larger clusters of very thin plates. We 
then seeded this improved condition with seed stock made from the original urchins and 
obtained single plates (see fig. 4.3). The largest of these plates measured 10 x 30 x 5 µm 
and diffracted to 8 Å at the 24-ID-E micro-beamline at ANL (see fig. 4.4). The images 
collected were indexed and the crystals had a P2 primitive monoclinic lattice with unit 
cell dimensions a= 130.9 Å, b= 173.5 Å, c = 241.1 Å, α = β =  90 γ =95.79, volume 
=5,447,723 Å3. These dimensions would allow for 3 copies of RNAP in the asymmetric 
unit with 48.5% solvent content and a Matthews coefficient of 2.39 Å3 /Dalton which are 
within the empirically observed range for protein crystals 11 and thus the unit cell is 
consistent with the crystals containing Ec RNAPΔα-CTD. 
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4.4 Discussion 
We obtained crystals of Ec RNAPΔα-CTD that diffracted weakly. To our knowledge, 
this is the first time that diffracting crystals of Ec RNAP have been obtained. However, 
these crystals were not suitable for data collection as they required long exposure times 
and suffered from radiation damage.  
 
That addition of the extra ω-expression plasmid improved the reproducibility of obtaining 
crystals was not surprising as this subunit is believed to have a key chaperone role and be 
important for core assembly 7. 
  
We have tried nearly every trick in the book to further optimize these crystals to no avail.  
Further modifications of the protein construct might be necessary for any further 
improvements in diffraction. One feature of RNAP that might be a concern for our 
preparations is the β’ zinc-binding domain. This domain was disordered in the Taq core 
structure 8, was “difficult to interpret” in the Taq holoenzyme 9 and had no secondary 
structure in the Tth holoenzyme 2.  The zinc bound by this domain acts as a chaperone to 
keep this region structured 10. This may be an issue in our purification protocol as we use 
1-5 mM DTT in the buffers throughout the preparation except for the IMAC stage, and 
the final protein buffer contained both 5 mM B-ME and 5 mM DTT -reducing agents that 
may strip zinc from the protein. Another modification that might improve diffraction is 
the removal of dispensable region 2 from within the β subunit, we recently solved this 
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structure (see Chapter 6) and found that this non-conserved insert forms two long helices 
that extend away from the globular core of RNAP and might prevent tight crystal 
packing.  There has been no function assigned to this region and it can be removed 
without any affect on in vitro function 13. 
 
The thermophilic RNAP structures were solved despite regional areas of disorder due to 
the α-CTD and the β’ zinc-binding domain. Thermophilic proteins are more amenable to 
crystallography as they must have more rigid structures to cope with life at high 
temperatures. It may be useful to search for a thermophilic relative of Ec that is 
susceptible to drugs, inhibitors and protein factors that target gram-negative bacteria, for 
future structural studies. The structure of the Ec RNAP, of course, remains an ambitious 
but worthy goal.  
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Chapter 5: Studies of Q proteins from lambda and 82 phages 
 
Introduction  
Phage invade bacterial cells and subvert host cell machinery, including RNAP, for their 
own needs. The Lambda and 82 phage Q antitermination proteins (λQ and 82Q) bind and 
remodel host Ec RNAP so that the Q-RNAP complex transcribes through termination 
sequences in the late gene operon. The Lambda and 82 Q proteins share no sequence 
homology but are functional homologs -the details described below are for λQ but are 
very similar for the two proteins (reviewed in 1).  
 
λQ acts at the phage late promoter (λPR’) via the Q utilization sequence (qut) that 
contains two crucial elements; a Q binding element (QBE) between the -35 and -10 
promoter elements and a downstream pause-inducing element. The σ70-RNAP 
holoenzyme (Eσ70) initiates transcription from this promoter but encounters the pause-
inducing element after transcribing 16-17 nt. The pause-inducing element is a -10-like 
sequence that interacts with σ702. In the absence of Q, Eσ70 pauses for about 30 seconds 
and then continues transcription until it reaches the termination sequence, TR’, 200 nt 
downstream. Q has both anti-pausing and anti-termination activity, thus in the presence 
of Q the pause is shortened and a Q-RNAP complex exits the pause and transcribes 
through TR’. 
102 
  
 
The mechanisms for Q anti-pausing and anti-termination are not fully understood but 
multiple lines of evidence have led to the following model (see fig. 5.1, reviewed in 1, 
presented in 2). In Eσ70, the σ704 is bound to the β flap and σ702 is bound to the β coiled-
coil, positioned to interact with the -35 and -10 elements 3; 4. At qut,  the Eσ70 must clear 
the promoter in order for Q to bind the QBE. Thus, Q encounters Eσ70 where the σ703.2 
is presumed to be displaced from the RNA exit channel and the σ704-β flap interaction is 
destabilized due to the presence of a short RNA transcript 3. Q then interacts with σ704, 
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stabilizing σ704 binding to a -35-like element that is just 1 bp upstream from the pause-
inducing -10 element 5. This allows Q to bind the β-flap and may place structural tension 
on σ70 that promotes its release from RNAP. Q forms a stable component of the ensuing 
elongating complex and can travel with RNAP up to 22 kilobases 6.   
 
We were able to purify λQ in a soluble form that was highly active. Unfortunately, we 
were unable to generate crystals of this protein suitable for data collection. 
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5.2 Methods 
5.2.1 λQ Protein expression and purification 
The λQ gene was PCR amplified from pACQ (gift from Bryce Nickels) and subcloned 
into a pET21a (Novagen) vector between NdeI/BamHI sites to generate pET21a_λQ.  
 
BL21(DE3) cells transformed with pet21a_λQ were grown in LB plus 200 µg ml−1 
ampicilin at 37°C to mid-log phase, then the temperature was lowered to 16°C and 
expression was induced with the addition of isopropyl β-d-thiogalactopyranoside to 
1mM. The cells were harvested 16 hours after induction by centrifugation, resuspended in 
buffer A (10 mM Tris pH 8.0, 200 mM NaCl, 5% glycerol, 0.1 mM EDTA, 10 mM DTT) 
supplemented with 1 mM PMSF and 0.5X EDTA-free protease-inhibitor cocktail (Sigma) 
and lysed using a French press. The clarified lysate was applied to a heparin column 
equilibrated with lysis buffer, the column was washed with 30 column volumes (CV) of 
buffer A and then bound proteins were eluted with a linear gradient of buffer A plus 0.2 – 
0.6 M NaCl over 20 CV.  The fractions containing λQ were pooled and diluted so that the 
final NaCl content of the buffer was approximately 150 mM. This diluted sample was 
applied to a HiTrap SP column equilibrated in buffer A, washed with 10 CV buffer A and 
bound proteins were eluted using bufferA plus a linear gradient of NaCl 100 mM – 1M 
over 20 CV. Fractions containing λQ were pooled and concentrated using centrifugal 
concentrators (Vivaspin, 5,000 MWCO) and then finally purified by size-exclusion 
chromatography on a SD75 column (GE Healthcare) equilibrated in buffer A plus 500 
mM NaCl. 
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Fractions containing λQ were pooled and dialyzed into storage buffer; 10 mM Tris-Cl, 
pH8.0, 200 mM NaCl, 10 mM DTT, snap frozen in liquid N2  and stored at -80°C. 
 
Plasmids encoding mutant λQ; Q(T101I,A160V,T165A), QE134K & QE141K, were 
gifts from Bryce Nickels. Truncated and mutant versions of λQ were similarly cloned and 
expressed. 
 
5.2.1 82Q Protein expression and purification 
The 82Q gene was PCR amplified from p82Qhis5 (gift from Jeffrey Roberts) and 
subcloned into a pET29a (Novagen) vector between NdeI/BamHI sites to generate 
pET29a_82Q, and into a pET28a-based vector between NdeI/BamHI sites as a 
hexahistidine-fusion protein to generate pSKB2-82Q. The his682Q protein was PCR 
amplified from pSKB2-82Q and cloned into pACYCDuet1_rpoZ via NotI/EcoRI sites. 
82Q was expressed from pET29a_82Q and purified using the λQ protocol described 
above.  
 
5.2.2 λQ + β  flap and 82Q + β flap protein expression  
An Ec rpoB gene fragment encoding amino acids 831-1057 (β flap) was PCR amplified 
from an Ec RNAP expression vector, pVS10 and cloned into a pet29a (Novagen) vector 
between NdeI/BamHI sites to generate pet29a_βflap. The λQ gene was PCR amplified 
from plasmid pACQ, and cloned into a pET28a-based vector between NdeI/BamHI sites 
as a hexahistidine-fusion protein to generate pSKB2-λQ. The hexahistidine-λQ fusion 
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was in turn PCR amplified along with upstream ribosomal binding site (rbs) and cloned 
into pET29a-β flap between EcoRI/NotI sites to generate pet29a-β flap-λQ.  The β flap-
82Q co-expression vector, pet29a-βflap was made in an identical manner. 
 
BL21(DE3) cells transformed with either construct were grown in LB plus 50 µg ml−1 
kanamycin at 37°C to mid-log phase, then the temperature was lowered to 16°C and 
expression was induced with 0.1 mM isopropyl β-d-thiogalactopyranoside for 16 hours. 
 
5.2.3 λQ + σ704 protein expression  
The pSKB2Ecσ704  expressing his6Ec σ70 residues 541–613 was a gift from other 
members of the laboratory 7.  
The his6Ecσ704 gene and upstream rbs was PCR amplified from pSKB2Ecσ704 and 
cloned into the pet21a_λQ plasmid to generate pet21a_λQ _ his6σ704. BL21(DE3) cells 
transformed with pet21a_λQ _ his6σ704were grown in LB plus 200 µg ml−1 ampicillin at 
37°C to mid-log phase, and expression was induced with 1 mM isopropyl β-d-
thiogalactopyranoside for 3 hours. Cells were lysed by French Press and the lysate was 
clarified by centrifugation at 10,000 rpm for 20 min. 
 
5.2.4 ICP-MS analysis of zinc content 
λQ protein samples were analysed for metal content by ICP-MS at the University of 
Wisconsin Soil & PlantAnalysis Lab, located in Madison, WI 
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5.2.5 Limited Proteolysis, N-Terminal Sequencing, and Mass Spectrometry 
Proteolytic digests were carried out in 20 mM Tris-HCl (pH 8), 50 mM NaCl, 5% (v/v) 
glycerol, 0.1mM EDTA. To form the λQ-DNA complex λQ was incubated with a 2.5-
fold excess of Qut-containing DNA on ice for 30 minutes. 1 nanomole of  λQ or λQ-
DNA complex was digested in a 20 uL volume with differing concentrations of trypsin 
(1-10 picomoles), and chymotrypsin (1-15 picomoles) for 60 min at 25°C. Reactions 
were terminated by the addition of Laemmli loading buffer and boiling. Reaction 
products were analyzed on denaturing 4-12% gradient NuPage Bis-Tris gels (Invitrogen) 
followed by Coomassie blue staining.  
 
Preparative samples for N-terminal sequencing were separated on 4-12% gradient 
NuPage Bis-Tris gels (Invitrogen) and blotted onto PVDF membrane (Bio-Rad). 
Fragments were excised and submitted for N-terminal sequence analysis at the protein 
sequencing facility at the University of Texas Medical Branch, Galveston, TX. 
 
Samples for MALDI-MS were prepared using the ultra-thin layer method 8. The MALDI 
plate was covered with a saturated solution of 4HCCA (1:3:2 (v/v) formic 
acid:water:isopropanol) allowed to dry for a few seconds and then the excess was wiped 
off. The samples were then spotted this plate, allowed to crystallize on the matrix and 
excess liquid was removed by vacuum. The spots were then overlaid with a drop of cold 
0.1% TFA solution that was allowed to stand for 15 seconds before being removed by 
vacuum. MALDI-MS data was obtained on a Voyager linear time-of-flight instrument. 
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5.2.6 Electrospray Ionisation - Mass Spectrometry (ESI-MS) 
Zachary Quinkert in the laboratory of Brian Chait conducted the ESI-MS analyses. 
Samples were were buffer exchanged into 0.5 M ammonium acetate using 
microcentrifuge columns (Bio-Spin, BioRad Laboratories, Hercules, CA) at room 
temperature prior to injection. 
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5.3 Results 
5.3.1 Expression and purification of soluble λQ 
The λQ protein was reported to be largely insoluble and has previously been purified 
from inclusion bodies and re-folded (eg. 9).  Re-folded denatured proteins can aggregate, 
which may explain why previous attempts to crystallize λQ failed 10. Therefore, we 
modified the standard procedure by inducing expression for an extended time at a lower 
temperature with a low concentration of IPTG; 16 hours, 16°C, 0.1 mM IPTG. These 
modifications are thought to slow the rate of target gene transcription to synchronize with 
host translation and chaperone functions. We were thus able to obtain Q protein in a 
soluble form that could be purified to high homogeneity by standard chromatographic 
techniques without a re-folding step (see fig. 5.2). Typically we obtain a yield of 2 mg of 
λQ at >95% purity per liter of culture. This protein was found to be highly active in 
antitermination assays (personal communication; C. Roberts & P. Deighan). 
 
5.3.2 Four strategies for crystallization of λQ were pursued 
With soluble protein in hand we pursued four strategies for crystallization. The first was 
to screen λQ alone. This strategy was quickly dismissed as the λQ precipitated in many 
of the crystal screen conditions. The remaining strategies involved forming a complex 
between λQ and either 1) the QBE DNA, 2) σ704, or 3) the β flap. Protein complexes can 
be more amenable for crystallization as they form more globular forms with less disorder. 
Furthermore, it has been observed that in crystals of DNA-protein complexes the DNA 
drives crystallization by packing end-to-end to form a pseudo-continuous helix 11. 
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5.3.3 Limited proteolysis indicates that the N-terminal region of λQ is unstructured. 
 
Limited proteolysis has been used extensively in crystallography to probe for protease-
resistant fragments likely to be in a compact globular form that facilitates ordered crystal 
packing.  Secondary structure predictions suggest that the N-terminal region of λQ is 
unstructured, and this is supported by an observation that λQ was degraded during 
crystallization trials to a truncated form missing up to 56 N-terminal residues 
(Santangelo, PhD thesis).  Therefore, we used various concentrations of trypsin, and 
chymotrypsin to probe the protease susceptibility of λQ in free-form and bound to DNA 
prior to setting up crystallization trials.  
 
We found that λQ–DNA was more protease-resistant than free λQ but eventually 
digested in a similar pattern (see fig. 5.3). We mapped the resulting protein fragments 
using mass spectrometry and Edman sequencing. As expected, these fragments were 
missing residues from the N-termini. We repeated these experiments several times and 
based on these analyses, three truncated versions of Q, starting at residue 10, 32 and 56 
were cloned into the Novagen pET 21a vector and all three were found to have a 
similar expression and solubility to the full length Q.  The three truncated Q proteins 
were purified using the same protocol as for the full-length protein. 
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5.3.4 λQΔHis56 bound to DNA crystallizes  but the crystals are not suitable for data 
collection.  
The λQΔHis56 protein was incubated with four different DNA species corresponding to 
the Qut with additional nucleotides forming blunt or overhanging ends to facilitate crystal  
packing (see fig. 5.4 A). The resulting complex was used in crystallization trials using a 
sparse matrix designed for protein-DNA complexes, the Nucleix suite (Qiagen).  Several 
candidate crystal forms were obtained including rectangular prisms that seemed very 
promising (see fig. 5.4 B). However, these crystals proved to contain only DNA and the 
various other “hits” were likewise found to contain just DNA, were too small for analysis 
or only diffracted weakly (eg. fig. 5.4 C).    
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5.3.5 λQ binds zinc. 
We were surprised to obtain multiple crystal forms that contained DNA alone as this has 
not occurred in other protein-DNA complex projects in the laboratory. Furthermore, the 
λQ had been shown to be active in anti-termination assays and was shown to bind DNA. 
λQ is presumed to bind zinc via a zinc-finger motif (cys 118, 121, 144, and 147; 
CX2CX22CX2C) 12, and is also known to be sensitive to oxidation. However, zinc binding 
has not been established experimentally. Zinc often has a structural role and zinc content 
has been shown to be sensitive to both oxidation and to chelation by reducing agents used 
in purification buffers 13. Therefore, we modified the buffers in the λQ purification and 
then submitted samples of the resulting protein for ICP-MS analysis of zinc content. λQ 
was found to contain 0.8 – 2.0 molecules of zinc per λQ monomer depending on the 
buffer content (see table 5.1). These results were somewhat inconsistent but could be 
interpreted as λQ tightly binding one zinc, presumably in the zinc-finger, and loosely 
binding a second zinc elsewhere. There is no obvious second site for zinc-binding 
although a sequence analysis tool ZincFinder 14 gave weak predictive scores for His 56, 
His122, Cys191 and Glu195 (see fig. 5.5). 
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Table 5.1 ICP-MS analysis of zinc binding by λQ 
 
Buffer 
conditions 
Reducing 
agent in 
purification 
buffers 
Reducing 
agent in 
storage 
buffer 
[Lambda Q] 
mg/mL, µM 
[Zinc 
bound] 
ppm, µM  
 
Zinc/λQ 
Standard  10 mM DTT 10 mM DTT 3.08, 137 10.59, 166 1.2 
10 µM Zinc 
added 
2 mM B-ME 2 mM B-ME 3.32, 148 12.02, 184 0.8 
10 µM Zinc 
added 
2 mM B-ME 10 mM DTT 2.79, 124 16.59, 254 2.0 
Degassed,10 
µM Zinc 
added 
10-15 mM B-
ME 
10 mM B-
ME 
2.31, 102.8 12.31, 188 1.8 
Degassed,10 
µM Zinc 
added 
 10 mM DTT 2.25, 100.1 8.22, 125 0.8 
Degassed,10 
µM Zinc 
added* 
10 mM B-ME 7.5 mM 
TCEP 
1.32, 58.7 5.54, 84.8 1.4 
Degassed,10 
µM Zinc 
added* 
10 mM B-ME 7.5 mM B-
ME 
1.32, 58.7 5.42, 82.9 1.4 
Degassed,10 
µM Zinc 
added* 
10 mM B-ME 7.5 mM 
DTT 
1.48. 65.9 5.15, 78.7 1.2 
*Protein from this preparation was dialyzed before storage in two steps; for step 1 the 
buffer contained 10 mM B-ME and no zinc and thus removed any unbound zinc, for step 
2 cthe buffers ontained the various reducing agents listed. 
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5.3.6 λQ does not form a stable complex with σ704 in solution.  
It has been shown that λQ interacts with σ704. The σ704 alone is insoluble but was 
successfully co-crystallized with Rsd by another member of the laboratory 7.  We hoped 
that co-expressed λQ and his6-σ704 would form a stable, soluble complex. However, the 
co-expressed proteins did not stably interact and his6-σ704 was found mostly in the 
insoluble fraction and λQ in the soluble fraction (see fig. 5.6). Clarified cell lysate  
containing the co-expressed proteins was applied to a metal affinity column but no 
detectable his6-σ704  or his6-σ704/λQ complex bound (data not shown). 
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5.3.7 82Q co-purifies with RNAP.  
Due to the variable results for λQ zinc binding and the unsuccessful crystallization trials, 
we decided to investigate whether another Q protein might be more suited for our studies. 
The lambdoid Phage 82 has a Q protein with no sequence similarity to λQ but with 
analogous anti-pausing and anti-termination functions. This protein has no cysteine 
residues and does not bind zinc. 82Q was cloned, expressed and purified in a similar 
manner to λQ.  However, this protocol did not generate pure 82Q but rather enriched for 
an 82Q-RNAP complex (see fig. 5.6). An analysis by ESI-MS indicated that 82Q binds 
RNAP as a dimer to give a combined mass of 441,781 Da, (measured 444,232, see fig 
5.7). 
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5.3.8 λQ and 82Q may form stable complexes with the β flap.  
The λQ interaction with σ704 is expected to be transient; σ70 is displaced from the 
elongating RNAP whereas λQ remains bound. Indeed, λQ binds the β flap and competes 
with σ704 for the same binding surface; the flap tip helix 2.  We co-expressed both λQ and 
82Q with the β flap. When these proteins are co-expressed at 30°C there is no apparent 
complex formation. However, when these proteins are co-expressed at 16°C it is possible 
that they do form complexes (see fig. 5.8 and fig. 5.9). The His6-λQ and the β flap are too 
close in size to distinguish them by SDS-PAGE, but the His6-82Q and β flap are 
distinguishable and protein bands matching these proteins masses are eluted from ni+-
beads analysed by SDS-PAGE. This crude purification is not definitive but is suggestive 
that 82Q, at least, does stably interact with the β flap. 
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5.4 Discussion   
The Q proteins were amongst the first proteins found to direct transcription by affecting 
the elongation step. A structure of Q may reveal the mechanism by which these proteins 
affect the RNAP to allow anti-transcription. We were unable to generate a crystal 
structure of Q but hope that the information generated by our studies will be useful for 
further work.   
 
Although we were able to purify soluble λQ, this protein may not have a stable tertiary 
structure, and in particular may be prone to losing a loosely bound zinc molecule.  We 
obtained weakly diffracting crystals of the λQΔHis56 protein bound to DNA but due to 
time constraints these crystals were not improved nor analyzed to confirm that they 
contained the intact λQΔHis56 protein.  
 
We were unable to obtain a λQ-σ704 complex, possibly because this interaction is 
transient or possibly because the interaction is mediated by DNA 5. The co-expression of 
either λQ or 82Q with the β flap may be a promising route to follow. The λQ interaction 
with the β flap can be strengthened by the mutation of three residues; T101I, A160V, 
T165A 2 and this mutant should be used in future work. The  λQ(T101I, A160V, T165A) 
was shown to bind RNAP from solution in vitro without any requirement for the Qut 
DNA sequence.  
 
The 82Q also had a robust interaction with the β flap interaction in bacterial two-hybrid 
assays 2. While the  λQ(T101I, A160V, T165A) was shown to bind RNAP from solution 
125 
in vitro, we found that 82Q co-purified with RNAP suggesting that 82Q is able to bind 
RNAP from solution in vivo without any dependence on phage DNA elements. A co-
expression system for 82Q + RNAP has been made by cloning the His682Q gene into the 
pACYC-rpoZ plasmid described in chapter 4 which is compatible with the Ec RNAP 
expression vector, pVS10. This system could be used to produce the 82Q-RNAP complex 
for further analysis. It would be important to test whether this 82Q-RNAP complex was 
active in anti-termination assays as at this stage we do not know whether it is the 
biologically relevant complex. 
 
Considering the difficulties we have had in obtaining a crystal structure of Ec RNAP 
alone, it seems unlikely that one could obtain a crystal structure of the 82Q-RNAP 
complex. However, the 82Q-RNAP complex may be suitable for cryo-Electron 
Microscopy (Cryo–EM). Previous Cryo-EM efforts in our laboratory focused on the 
(refolded) lambda Q protein and were unsuccessful – lambda Q was incubated with 
RNAP helical crystals but there was no density corresponding to lambdaQ in the 
resulting cryo-EM maps (personal communication N. Opalka). Either the 82Q or the 
λQ(T101I, A160V, T165A) with their higher affinity for RNAP may be more successful 
for this approach. Cryo-EM could provide a low resolution structure that would at least 
indicate where Q binds RNAP and may provide some low resolution details about Q 
function.  
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Appendix 4.6 Sequences of the modified rpoA gene used to produce Ec. 
RNAPΔαCTD.  
Plasmid backbone is pET21a (ampicillin resitance). Fragment cloned between Nde I 
(CATATG) and Blp I site (GCTNAGC). 
 
1. DNA encoding E. coli alpha subunit in blue coloured text; PPX site (between residues 
234-241) in red colored text. Uncleavable decahistidine tag appended to the 3 prime 
end of rpoA in green coloured text; cloned between NheI and NcoI / BamHI 
sites.*PPX PreScission™ Protease Amersham cuts between Gln and Gly of 
LEVLFQGP 
 
2. DNA encoding thermostable kanamycin resistance cassette in orange colored text  
 
3. DNA immediately downstream of T. thermophilus HB8 rpoC (purple colored text) –  
this is present as the starter plasmid fro this construct was pRecT.thHB8rpoC::PrA. 
 
 
CATATGcagggttctgtgacagagtttctaaaaccgcgcctggttgatatcgagcaagtgagttcgacgcacgccaaggtg
acccttgagcctttagagcgtggctttggccatactctgggtaacgcactgcgccgtattctgctctcatcgatgccgggttgcgc
ggtgaccgaggttgagattgatggtgtactacatgagtacagcaccaaagaaggcgttcaggaagatatcctggaaatcctgctc
aacctgaaagggctggcggtgagagttcagggcaaagatgaagttattcttaccttgaataaatctggcattggccctgtgactgc
agccgatatcacccacgacggtgatgtcgaaatcgtcaagccgcagcacgtgatctgccacctgaccgatgagaacgcgtctat
tagcatgcgtatcaaagttcagcgcggtcgtggttatgtgccggcttctacccgaattcattcggaagaagatgagcgcccaatc
ggccgtctgctggtcgacgcatgctacagccctgtggagcgtattgcctacaatgttgaagcagcgcgtgtagaacagcgtacc
gacctggacaagctggtcatcgaaatggaaaccaacggcacaatcgatcctgaagaggcgattcgtcgtgcggcaaccattct
ggctgaacaactggaagctttcgttgacttagaagttttatttcagggtccagtgaaagaagagaaaccagagttcgatccgatcc
tgctgcgccctgttgacgatctggaattgactgtccgctctgctaactgccttaaagcagaagctatccactatatcggtgatctggt
acagcgtaccgaggttgagctccttaaaacgcctaaccttggtaaaaaatctcttactgagattaaagacgtgctggcttcccgtg
gactgtctctgggcatgcgcctggaaaactggccaccggcaagcatcgctgacgagGCTAGCcatcaccatcaccatcat
caccatcaccattaaCCATGGGGATCCccgggagtataacagaaaccttaaggcccgaccgcttgacaagggcgc
gtgaggttttacgatagcgccggatgcggggaaaaagggctccttttggggggttttccccgcaccgggcggacctgggcgg
agaggaaacgcggcaactcgcccgtctcgggttcccgcccacgacccttaaggaggtgtgaggcatatatgaatggaccaata
ataatgactagagaagaaagaatgaagattgttcatgaaattaaggaacgaatattggataaatatggggatgatgttaaggctatt
ggtgtttatggctctcttggtcgtcagactgatgggccctattcggatattgagatgatgtgtgtcatgtcaacagaggaagcagag
ttcagccatgaatggacaaccggtgagtggaaggtggaagtgaatttttatagcgaagagattctactagattatgcatctcaggt
ggaatcagattggccgcttacacatggtcaatttttctctattttgccgatttatgattcaggtggatacttagagaaagtgtatcaaac
tgctaaatcggtagaagcccaaaagttccacgatgcgatttgtgcccttatcgtagaagagctgtttgaatatgcaggcaaatggc
gtaatattcgtgtgcaaggaccgacaacatttctaccatccttgactgtacaggtagcaatggcaggtgccatgttgattggtctgc
atcatcgcatctgttatacgacgagcgcttcggtcttaactgaagcagttaagcaatcagatcttccttcaggttatgaccatctgtg
ccagttcgtaatgtctggtcaactttccgactctgagaaacttctggaatcgctagagaatttctggaatgggattcaggagtggac
agaacgacacggatatatagtggatgtgtcaaaacgcataccattttaaGGTACCgcccgccccgcaaggtggaggccc
ccggtttccccgggggcctttttccggcataatgggcccgtgcgcgcccggttgtacgccgcgttccgtcaggtgggcgagga
cctcttcgcccagggcctcatctccgccacggccgggaacttctccgtgcgcaccaagggggggttcctcatcaccaaaagcg
gggtgcagaaggcgaggctcaccccggaggacctcctggaggtgcccttggaagggcccatccccgaaggggcgagcgtg
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gagagcgtggtccaccgggaggtctaccgcaggaccggggcccgggccctggtccacgcccacccccgggtggccgtggc
cctctccttccacctctcccgcctaaggcctttggacctcgagggccagcactacctgaaggaggtcccggtcctcgcccccaa
gacggtctccgccacggaggaggcggccttgagcgtggccgaggccttgcgggagcaccgggcctgcctcctgagggggc
acggggccttcgccgtgggcctgaaggaggccccggaggaggcccttctcgaggcctacggcctcatgaccaccctggagg
agagcgcccagatcctcctctaccaccgcctctggcagggggcggggcccgccttggggggtggggaatgagggtcctcttc
gtggaggggaaggaccgggaggccctggtggccctggcggaggccctgccccatccctactggctcctcgaggGAATT
CGCTGAGC 
 
 
Modified RpoA has a mass of 37, 930 Da. PPX cleavage results in two subunits CTD 11, 
521 Da 
NTD 26, 298 Da 
 
Alpha_ppx_CTD_(His)10: 37, 930 Da 
MQGSVTEFLKPRLVDIEQVSSTHAKVTLEPLERGFGHTLGNALRRILLSSMPGCA
VTEVEIDGVLHEYSTKEGVQEDILEILLNLKGLAVRVQGKDEVILTLNKSGIGPVT
AADITHDGDVEIVKPQHVICHLTDENASISMRIKVQRGRGYVPASTRIHSEEDERP
IGRLLVDACYSPVERIAYNVEAARVEQRTDLDKLVIEMETNGTIDPEEAIRRAATI
LAEQLEAFVDLEVLFQGPVKEEKPEFDPILLRPVDDLELTVRSANCLKAEAIHYIG
DLVQRTEVELLKTPNLGKKSLTEIKDVLASRGLSLGMRLENWPPASIADEASHHH
HHHHHHH. 
 
Wildtype alpha 36, 510 Da 
MQGSVTEFLKPRLVDIEQVSSTHAKVTLEPLERGFGHTLGNALRRILLSSMPGCA
VTEVEIDGVLHEYSTKEGVQEDILEILLNLKGLAVRVQGKDEVILTLNKSGIGPVT
AADITHDGDVEIVKPQHVICHLTDENASISMRIKVQRGRGYVPASTRIHSEEDERP
IGRLLVDACYSPVERIAYNVEAARVEQRTDLDKLVIEMETNGTIDPEEAIRRAATL
AEQLEAFVDLRDVRQPEVKEEKPEFDPILLRPVDDLELTVRSANCLKAEAIHYIG
DLVQRTEVELLKTPNLGKKSLTEIKDVLASRGLSLGMRLENWPPASIADE. 
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Chapter 6: Gp33 – a co-activator with a novel modus operandi. 
 
6.1 Introduction 
T4 bacteriophage infect Ec and hijack the host RNAP, re-directing it to transcribe the T4 
genome. The general mechanisms for switching transcription to the T4 genome begins 
with the T4 DNA being distinguished from the host DNA by its glucosylated, 
hydroxymethylated cytosines 1. This allows the T4 protein Alc to specifically terminate 
transcription on Ec DNA and allows phage nucleases to specifically digest host DNA. A 
finer mechanism is provided by the T4 proteins Alt and ModA, which ADP-ribosylate 
Arg265 of the RNAP α-CTD subunits, thus preventing activation by DNA UP-elements 
or DNA bound catabolite activator protein 1. Alt also ADP-ribosylates other arginine 
residues on RNAP and other host proteins 1. 
 
The temporal regulation of T4 genes involves manipulation and mimicry of σ70 function; 
promoter recognition and DNA melting. The domain organization of the σ70 family has 
been characterized based by sequence alignment 2, proteolysis 3, and structure 4; 5; 6; 7; 8. 
There are four well-conserved domains; σ1 functions as an autoinhibitor 8, σ2 recognizes 
the -10 element (TATAAT) and mediates melting of  double stranded DNA 4; 6; 7, σ3 
binds extended -10 elements (TGnTATAAT) 9; 10 and σ 4 binds the -35 element 
(TTGACA). 
 
The T4 genome has three classes of promoters; early, middle and late. T4 early genes 
have strong promoters consisting of a -35 element similar to Ec (consensus GTTTAC) 
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and a very strong -10 element that can extend even beyond the Ec extended -10 elements 
(eg. GTGGTATTAT), and are transcribed by σ70-holoenzyme with and without ADP-
riboslyations 1.  The general modifications combined with strong promoters are sufficient 
to support transcription of the T4 early genes 1. 
 
Middle gene promoters also have strong -10 elements but the -35 element is functionally 
replaced by the Mot box, a 9 bp sequence centered at -30 that is recognized by T4-
encoded motA 11. MotA and AsiA are two T4 early gene products that modify the σ70-
holoenzyme so that it preferentially transcribes T4 middle genes. AsiA acts as an 
inhibitor by binding to σ704 and preventing it from interacting with -35 elements, and 
works in concert with MotA as an appropriator to recruit the σ70-holoenzyme to middle 
gene promoters 11; 12. AsiA and MotA also increase the rate that σ70-holoenzyme clears 
the promoter and begins elongation 13. 
 
The T4 late gene promoters consist of only an extended -10-like element 
(TATAAATA)14.  Transcription from these promoters does not rely on the σ70 but rather 
on two T4 proteins, Gp55 and Gp33, that together form a functional σ analogue (see 
figure 6.1) 15; 16. The -10 element is recognized by Gp55, a very divergent member of the 
σ70 family less than one third the size of σ7017. Gp55 has weak sequence homology to σ2 
and, like σ2, binds the RNAP β’ coiled-coil 18. Gp55 bound to Ec RNAP is sufficient for 
specific initiation at late promoters in vitro 16.  Gp33 has no homology to σ, yet binds to 
the RNAP β flap like σ4 and activates transcription15. This activation requires active 
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DNA replication and a subunit of the T4 DNA replisome, gp45 19. 
 
 
 
Gp45 is a sliding clamp protein, a subunit of the phage DNA replisome that is loaded 
onto DNA at the primer-template junctions in the replication fork by the clamp loader 
complex Gp44/Gp62 20. Trimers of Gp45 form a ring that encircles and slides along 
DNA, tethering the catalytic subunit of DNA polymerase, Gp43, to the DNA 21. Gp45 
actually binds both Gp55 and Gp33 to synergistically activate transcription, but the 
interaction with Gp33 has more substantial effect than the interaction with Gp55 19. The 
binding determinant for Gp45 in both these proteins (as well as Gp43) is a carboxy-
terminal hydrophobic “tail” with the conserved motif (S/T)LDFL(F/Y/L) 19; 22; 23. Gp45 
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can slide along the DNA to activate transcription from late gene promoters more than 1 
kb from where it is initially loaded and can carry both Gp33 and Gp55 so that they too 
track along the DNA 24; 25. 
 
The crystal structures of a number of σ70 family members have been solved and it has 
been observed that even distantly related members have highly conserved σ2 and σ4 
structures 5. It has been proposed that σ2 and σ4 are the minimal requirements for σ to 
recognize a bipartite promoter 5, but in the case of the T4 late gene promoters there is 
only a single DNA element for σ to recognize and thus a single σ domain is sufficient.  
Gp33 may be a functional analogue to σ4 however it has a distinct modus operandi; it 
does not bind DNA and instead provides an additional DNA-interaction by binding to 
Gp45. Therefore, it would not be expected to be structurally similar to σ4. 
 
Gp33 is thought to be unstructured or in an extended alpha-helical conformation in 
solution 26, so we set-out to crystallize Gp33 in complex with the β flap. This complex 
was well behaved in solution and could be readily purified using standard 
chromatographic techniques in quantities suitable for crystallography. Here, I describe 
the preliminary results for the 3.3 Å-resolution X-ray crystal structure of the Gp33/Ec 
beta flap(831-1057) complex. 
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6.2 Methods 
6.2.1 Protein expression and purification 
An Ec rpoB gene fragment encoding amino acids 831-1057 (beta flap) was PCR 
amplified from an Ec RNAP expression vector, pVS10 and subcloned into a pet29a 
(Novagen) vector between NdeI/BamHI sites to generate pet29a_betaflap. The T4 gp33 
gene was PCR amplified from plasmid pGP33NHis (gift from Vikas Jain, Peter 
Geiduschek) and subcloned into a pET28a-based vector between NdeI/BamHI sites as a 
hexahistidine-fusion protein to generate pSKB2-GP33. The hexahistidine-Gp33 fusion 
was in turn PCR amplified and subcloned into pET29a-Betaflap between EcoRI/NotI 
sites to generate pet29a-betaflap-GP33. 
 
BL21(DE3) cells transformed with pet29a-Betaflap-GP33 were grown in LB plus 50 µg 
ml−1 kanamycin at 37°C to mid-log phase, then the temperature was lowered to 16°C and 
expression was induced with 0.5 mM isopropyl β-d-thiogalactopyranoside for 16 hours. 
The cells were then harvested by centrifugation, resuspended in IMAC-A buffer (20 mM 
Tris pH 8.0, 500 mM NaCl, 5% glycerol, 0.5 mM β-mercaptoethanol) supplemented with 
1 mM PMSF and EDTA-free protease-inhibitor cocktail (Sigma) and lysed using a 
French press.  The clarified lysate was loaded onto an IMAC HiTrap column (GE 
Healthcare) charged with Ni2+ ions and pre-equilibrated with IMAC-A buffer. The 
column was washed with 10 column volumes of IMAC-A plus 5 mM imidazole, 
followed by 10 column volumes of IMAC-A plus 25 mM imidazole and then bound 
proteins were eluted with IMAC-A plus 250 mM imidazole. The eluted proteins were 
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digested overnight with PreScission protease (GE Healthcare) and simultaneously 
dialyzed against IMAC-A buffer at 4°C before being applied to a second, subtractive, 
IMAC HiTrap column to remove non-specific and uncleaved protein. The flowthrough 
was precipitated by adding ammonium sulfate to 60% saturation, pelleted by 
centrifugation and then resuspended in gel filtration buffer (10 mM Tris-HCl pH 8, 5% 
glycerol, 0.1 mM EDTA, 1 mM DTT). Finally, the GP33 - beta flap complex was 
purified by size-exclusion chromatography on a SD75 column (GE Healthcare). 
 
Selenomethionyl-substituted protein was produced using the same protocol as for the 
native protein except that cells were grown in M9 minimal media supplemented with 
selenomethionine 10 mg/mL (CalBiochem) and 2.5 mg/mL isoleucine, lysine, and 
threonine to block endogenous methionine biosynthesis 27. The selenomethionyl-
substituted protein was purified using the same protocol as for the native protein except 
that the flowthrough from the second IMAC column was concentrated using centrifugal 
concentrators (Vivaspin, 5, 000 MWCO). 
 
Both native and selenomethionyl-substituted protein were dialysed into a final storage 
buffer consisting of 10 mM Tris pH 8.0, 150 mM NaCl , 1% glycerol, 1 mM β-
mercaptoethanol and 1 mM DTT. 
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6.2.2 Crystallization, data collection and processing. 
Crystallization screening trials were set up using vapor difusion with the JCSG+ screen 
(Qiagen Research). 12 candidate conditions were identified; JCSG+ conditions #10, 12, 
14, 15, 24, 59, 70, 74, 76, 78, 79, 80. Crystals suitable for structure determination were 
grown using hanging-drop vapor diffusion by mixing 1 µL of protein solution with 1 µL 
of reservoir solution above 0.5 ml of reservoir solution (0.1 M Tris pH 8.5, 0.1 M 
triethylamine N-oxide, 20% polyethylene glycol 2,000 monomethylether) with protein 
concentrations between 7.5 – 12 mg/mL at 22°C. These crystals belonged to the 
orthorhombic space group I212121, had 67% solvent content and contained one molecule 
of each protein per asymmetric unit. Crystals were cryoprotected by slow exchange of 
crystallization solution with 0.1 M triethylamine N-oxide, 23% polyethylene glycol 2,000 
monomethylether, 20% ethylene glycol and subsequent flash-freezing in liquid nitrogen. 
 
A full dataset was collected on a single crystal to 3.1 Å at X25, National Synchrotron 
Light Source (NSLS), Brookhaven National Laboratory (BNL). The data was processed 
with HKL2000 and SCALEPACK. A homology model of the beta flap was built using 
MODELLER 28 with the taq core RNAP crystal structure 29 as the template and Ec 
residues 831-891, 911-930, 1037-1057 aligned with the evolutionary conserved taq 
residues 703-763, 783-802, 807-830. The preliminary phases were obtained from 
molecular replacement using PHASER. 
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6.3 Preliminary results and discussion 
6.3.1 Crystallization, structure determination and preliminary structure of the β 
flap (831-1057)/gp33 complex. 
The β flap (residues 831-1057) was co-expressed with hexahistidine-tagged Gp33 and the 
soluble complex was purified to homogeneity using standard chromatographic techniques 
that included removal of the hexahistidine tag (see fig. 6.2 and methods).  Typical yield 
was about 7 mg/L culture. 
 
Crystals were obtained in 12 conditions from the JCSG+ screen (Hampton Research). 
These crystals varied from fine needle clusters to hexagonal plates as shown in figure 6.3.  
 
A complete data set to 3.3 Å-resolution was collected from the hexagonal plates 
(approximate dimensions 200 x 40 x 10 µm) produced in condition #72 (a single 
diffraction image is shown in fig. 6.4). The data collection statistics are summarized in 
table 6.1. The crystals contained one 38.4 kDa Beta flap/Gp33 complex per asymmetric 
unit with a solvent content of 67%. The structure was solved using molecular 
replacement using an Ec homology model based on a portion of the Taq β flap (residues 
831-890/912-935/1043-1057,  1L9Z) as the search model. 
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We were able to do some very preliminary building into the electron density map (see fig. 
6.5).  There is electron density around the beta flap-tip helix that we assume to 
correspond to Gp33. This area of the map was not sufficiently clear to allow us to build 
into it, however, when we tried to superimpose the flap-tip helix/σ4 from the taq  
holoenzyme structure 6 it is obvious that the density does not correspond to a σ4 
structural mimic. 
 
We were able to build two long helices into the map in the region corresponding to Ec 
dispensable region 2 (DR2). This region is not conserved in the taq enzyme and is seen 
here for the first time. Ec DR2 forms two long, parallel helices connected at the end by a 
short helix. 
 
Table 6.1 Diffraction and data statistics for E. coli β-flap/gp33 crystals. 
 
 Native crystals Selenomethionine-substituted crystals 
Crystallization 
condition 
0.1 M Tris pH 8.5, 0.1 M 
triethylamine N-oxide, 
20% polyethylene glycol 2,000 
monomethylether 
0.2 M potassium citrate 
20% PEG 3350 
Space group I222  I222  
Unit cell a = 55.04 Å  a = 55.218 Å  
 b = 109.93 Å  b = 112.250 Å  
 c = 165.73 Å  c = 164.847 Å  
β-flap/gp33 
complexes 
(38.4 kDa)/AU 
1  1  
Solvent content 65%  65%  
Resolution (Å) 3.3  3.0 
I/σI 21.0 (2.6)  21.9 (2.6)  
Rsym 0.086 (0.473)  0.053 (0.412)  
Completeness 
(%) 98.5 (90.2)  98.5 (90.2)  
Redundancy 7.5 (6.6)  3.0 (2.7)  
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6.5 Further structural analysis 
We have obtained multiple data sets from crystals containing selenomethionine-
substituted protein and will be using these to improve the phases of the current structure.  
We hope that these experimental phases will improve the electron density map and we 
will be able to build the Gp33 molecule as well as the missing beta-flap residues. The 
data collection statistics for the selenomethionine-substituted protein crystals is 
summarized in table 6.1.  
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